Document:

<PAGE>

                                                                    EXHIBIT 10.7

                                SUPPLY AGREEMENT

Confidential treatment has been requested for portions of this exhibit. The copy
filed herewith omits the information subject to the confidentiality request.
Omissions are designated as *. A complete version of this exhibit has been filed
separately with the Securities and Exchange Commission

BETWEEN:

(1)               ENDEAVOR PHARMACEUTICALS, INC., a corporation organized and
                  existing under the laws of the State of Delaware, with offices
                  at 127 Racine Drive, Suite 202, Wilmington, North Carolina
                  28403 (hereinafter referred to as "ENDEAVOR")

AND:

(2)               ORGANICS/LAGRANGE, INC., a corporation organized and existing
                  under the laws of the State of Illinois, with offices at 1935
                  Techny Road, Suite 14, Northbrook, Illinois 60062 (hereinafter
                  referred to as "ORGANICS")

(A)      WHEREAS, ENDEAVOR is in the business of the development, manufacture
and distribution of finished drug products; and

(B)      WHEREAS, ORGANICS is the owner of proprietary technology and is in the
business of the development, manufacture and distribution of APIs (as defined
below), including Substance (as defined below), which contain one (1) or more
Estrogen Sulfates (as defined below); and

(C)      WHEREAS, ENDEAVOR wishes to purchase Substance from ORGANICS for use in
the manufacture of Product (as defined below) under the terms and conditions set
out in this Agreement; and

(D)      WHEREAS, ORGANICS wishes to supply Substance to ENDEAVOR for use in the
manufacture of Product under the terms and conditions set out in this Agreement.

NOW THEREFORE, in consideration of the obligations hereinafter assumed and other
good and valuable consideration, the receipt and sufficiency of which is hereby
acknowledges ORGANICS and ENDEAVOR enter into this Agreement:

Article 1.        Definitions

When capitalized, the following terms shall, for all purposes of this Agreement,
have the meanings specified in this Article 1:

1.1      Agreement. "Agreement" shall mean this document together with all
         exhibits and/or amendments thereto.

                                      -1-
<PAGE>

1.2      API(s). "API" (Active Pharmaceutical Ingredient) or "APIs" shall mean
         any bulk drug substance that is represented for use in a finished drug
         product and that, when used as intended in the manufacturing,
         processing or packaging of such drug product, becomes an active
         ingredient of a finished dosage form of the drug.

1.3      Batch. "Batch" shall mean a specific quantity of Substance that is
         intended to have uniform character and quality, within specified
         limits, and is produced according to an order during the same cycle of
         manufacture.

1.4      Claim. "Claim" shall have the meaning defined in Section 9.4 of this
         Agreement.

1.5      Co-marketer. "Co-marketer" shall mean a third party having the right to
         participate with ENDEAVOR in the sales, marketing and/or distribution
         of Product.

1.6      Confidential Information. "Confidential Information" shall have the
         meaning defined in Article 6 of this Agreement.

1.7      Conjugated Estrogens. "Conjugated Estrogens" shall mean an API and/or
         finished drug product composed of a mixture of various Estrogen
         Sulfates such as, but not limited to, * and which exhibits an *of no
         less than *.

1.8      Contract Manufacturer. "Contract Manufacturer" shall mean a third party
         chosen by Endeavor to contract manufacture Product for Endeavor.

1.9      Contract Quarter. "Contract Quarter(ly)" shall mean any period of three
         consecutive calendar months commencing with the first day of any
         January, April, July, or October.

1.10     Delta. "Delta" shall mean the Delta Component supplied to ORGANICS by
         or on behalf of ENDEAVOR.

1.11     Delta Component. "Delta Component" shall mean *.

1.12     Delta Specifications. "Delta Specifications" shall mean the written
         standards established for the characteristics, quality, and quality
         control testing of Delta set forth in Exhibit B.

1.13     DMF(s). "DMF" or "DMFs" shall mean a Drug Master File as described
         under the United States Code of Federal Regulations in 21 CFR 314.420.

1.14     Estrogen Sulfate. "Estrogen Sulfate" shall mean any *.

1.15     FDA. "FDA" shall mean the United States Food and Drug Administration of
         the Department of Health and Human Services.

1.16     GMP(s). "GMP" or "GMPs" shall mean the current Good Manufacturing
         Practices regulations promulgated by the FDA and codified under United
         States Code of Federal Regulations in 21 CFR Parts 210 and 211, as
         amended.

1.17     Lot. "Lot" shall mean a Batch, or a specified identified portion of a
         Batch, having uniform character and quality within specified limits.

1.18     NDA. "NDA" shall mean one or more New Drug Applications filed with the
         FDA pursuant to the Food, Drug and Cosmetic Act of the United States
         and the regulations promulgated

         * Certain information on this page has been omitted and filed
         separately with the Securities and Exchange Commission. Confidential
         treatment has been requested with respect to the omitted portions.

                                      -2-
<PAGE>

         thereunder, including any amendments or supplements thereto and any
         documents incorporated therein by reference.

1.19     Product. "Product" shall mean ENDEAVOR'S Conjugated Estrogens tablets
         containing Substance alone or in combination with other pharmaceutical
         ingredients, manufactured by or for ENDEAVOR under ENDEAVOR'S NDA.

1.20     Producer Price Index. "Producer Price Index" shall mean the Producer
         Price Index for Industrial Commodities; Drugs, and Pharmaceuticals
         (06-3), published by the United States Department of Commerce.

1.21     Specifications. "Specifications" shall mean the written standards
         established for the characteristics, quality, and quality control
         testing of Substance set forth in Exhibit A.

1.22     Substance. "Substance" shall mean the API supplied by ORGANICS
         hereunder and intended to meet the Specifications set forth in Exhibit
         A hereto and which shall be referred to by ORGANICS as *.

1.23     Synthetic Conjugated Estrogens. "Synthetic Conjugated Estrogens" shall
         mean Conjugated Estrogens of any specification, including, but not
         limited to Substance, manufactured by synthesis from various steroidal
         components and which do not contain any substance or material of equine
         origin.

1.24     Term. "Term" shall refer to the term of this Agreement, as set forth in
         Section 8.1.

1.25     USA. "USA" shall mean the United States of America, its territories and
         possessions, including the District of Columbia. the Commonwealth of
         Puerto Rico, the Virgin Islands, Guam, and all other places under the
         jurisdiction thereof.

1.26     USP. "USP" shall mean the United States Pharmacopoeia, including, but
         not limited to, its supplements, monographs, and general notices and
         requirements.

Article 2.        Supply, Price, Payment

2.1      Supply. Subject to the provisions of Section 3.4 and Articles 4 and 6
         hereof, ORGANICS shall manufacture, or procure the manufacture, and
         supply to ENDEAVOR, and ENDEAVOR shall purchase from ORGANICS,
         ENDEAVOR'S total requirements of Synthetic Conjugated Estrogens APIs
         containing the Delta Component meeting the Specifications and any
         Synthetic Conjugated Estrogens APIs containing the Delta Component with
         substantially similar specifications (i.e. the same active estrogens
         content at the same ratios). ORGANICS shall not prepare for or sell to
         any third party other than Berlex Laboratories (pursuant to Berlex
         Laboratories' rights in force at the execution of this Agreement) a
         Synthetic Conjugated Estrogens API containing the Delta Component.

2.2      Price, Shipping Terms. The prices charged by ORGANICS to ENDEAVOR for
         Substance delivered to ENDEAVOR hereunder shall be as set forth in
         Exhibit C, which prices may be modified or changed each calendar year
         according to the provisions of Section 2.3, set forth hereinbelow.

         The shipping terms reflected on the invoices issued by ORGANICS for
         Substance shipped under this Agreement shall be FOB shipping point.

         * Certain information on this page has been omitted and filed
         separately with the Securities and Exchange Commission. Confidential
         treatment has been requested with respect to the omitted portions.

                                      -3-
<PAGE>

2.3      Price Increase.

         (a)      Pursuant to 2.3(b) and 2.3(c) hereof, ORGANICS shall have the
                  right to raise its then current price for Substance twice per
                  calendar year, such adjustments to be effective on January 1
                  and July 1 of the calendar year, provided that ORGANICS first
                  notifies ENDEAVOR in writing of such price increase at least
                  six (6) months prior to the effective date thereof, ORGANICS
                  may, at its option, increase its price pursuant to either
                  2.3(b) or 2.3(c), but not both, for any calendar year.

         (b)      *

         (c)      *

         (d)      Price increases pursuant to Section 2.3(c) hereof shall be
                  subject to audit for twelve (12) months following the end of
                  the year to which they apply, upon notice by ENDEAVOR within
                  such time period. The audit shall be conducted by an
                  independent auditor selected by ENDEAVOR and reasonably
                  acceptable to ORGANICS, who has executed a confidentiality
                  agreement acceptable to ORGANICS. Such auditor shall maintain
                  confidentiality as to the financial information reviewed and
                  shall disclose, in writing to ORGANICS and ENDEAVOR, only the
                  result of its audit as to the calculation of the price
                  increase. The costs of such audit shall be borne by the
                  non-prevailing party.

2.4      Invoices, Payments.

         (a)      For a "Preliminary Period," ENDEAVOR shall make an advance
                  deposit with respect to each purchase order. Each such advance
                  deposit shall be in the amount of fifty percent (50%) of the
                  total amount due for such purchase order and shall be paid to
                  ORGANICS within 10 calendar days of acknowledgement of the
                  purchase order by ORGANICS. Such Preliminary Period shall
                  begin on the effective date of this Agreement and shall
                  continue until ENDEAVOR shall have paid all amounts due
                  (including the advance deposit and remaining amounts) on a
                  timely basis for four (4) years, at which time ORGANICS shall
                  have the option to either: (i) eliminate the advance deposit
                  and accept payment upon shipment; or, (ii) pay interest to
                  ENDEAVOR on all advance deposits at the then effective
                  twenty-six (26) week Treasury Bill rate plus 100 basis points.

         (b)      Invoices issued by ORGANICS with respect to sales of Substance
                  shall be rendered via facsimile promptly after shipment and
                  the amount due on such invoices shall be paid to ORGANICS, in
                  United States currency, within thirty (30) days after the date
                  of invoice for each delivery of Substance accepted by ENDEAVOR
                  under the provisions of Section 4.7 of this Agreement. All
                  payments of advance deposits and of invoices shall be made via
                  electronic bank wire transfer to the account of ORGANICS as
                  specified by ORGANICS by written notice to ENDEAVOR.

         (c)      In the event ENDEAVOR shall, with respect to any delivery
                  hereunder, fail to make payment of the total amount due with
                  respect to the invoice relating to such delivery within thirty
                  (30) days after the date of such invoice, and shall fail to
                  remedy such default within five (5) business days after
                  receipt of written or facsimile notice of same from ORGANICS
                  ORGANICS may suspend its obligations hereunder until payment
                  for such delivery has been made and any such suspension shall
                  not constitute a breach of this Agreement, and/or may exercise
                  any other rights it may possess, either at law or in equity,
                  and/or may terminate this Agreement in accordance with Article
                  8 of this

                  * Certain information on this page has been omitted and filed
                  separately with the Securities and Exchange Commission.
                  Confidential treatment has been requested with respect to the
                  omitted portions.

                                      -4-
<PAGE>

                  Agreement; and/or, if such failure by ENDEAVOR shall occur
                  after the expiration of the Preliminary Period, ORGANICS may,
                  by notice to ENDEAVOR, re-impose therequirements of Section
                  2.4(a) for a period which shall begin forthwith and continue
                  until ENDEAVOR shall have paid all amounts due on a timely
                  basis for four (4) years.

         (d)      If ENDEAVOR shall pay ORGANICS fifty percent (50%) of the
                  amount due with respect to any purchase order as an advance
                  deposit as described in Section 2.4(a) hereof and the
                  remaining amount due net of applicable discount with respect
                  to such purchase order prior to the date of shipment specified
                  in the acknowledgment of such purchase order, ORGANICS shall
                  grant a discount of two percent (2%) with respect to the
                  entire amount due with respect to such purchase order.

Article 3.        Restrictions on Use Compliance

3.1      Restrictions on Use. ENDEAVOR agrees that: (a) it will nor use/or
         permit the use of, Substance supplied by ORGANICS for the manufacture
         of any finished drug products indicated for contraception, fertility
         control, or abortive use without the written permission of ORGANICS;
         (b) it will not sell or otherwise transfer any amount of Substance
         supplied by ORGANICS to any third party without the written permission
         of ORGANICS, except a transfer of Substance to a Contract Manufacturer
         who processes such Substance into Product for ENDEAVOR under ENDEAVOR'S
         NDA or tests to determine conformity to Specifications herein; (c) it
         will use or allow the use of Substance only for the development,
         manufacture, distribution and sale of Product; and, (d) during the term
         of this Agreement and for a period of ten (10) years following
         termination of this Agreement, it will not conduct any reverse
         engineering of Substance or cause or allow such reverse engineering to
         be conducted by others on ENDEAVOR'S behalf. For purposes of this
         Section, "reverse engineering" shall mean the use of Substance or
         ORGANICS' Confidential Information to (i) develop, or (ii) analyze for
         the purpose of developing, an API to replace Substance.

3.2      Compliance. ORGANICS agrees to promptly notify ENDEAVOR of all issues
         of which ORGANICS is aware which, as defined by applicable GMPs and
         other FDA requirements, may impact the regulatory status of Product,
         including but not limited to: (a) changes in ORGANICS' supplier(s) of
         steroids; (b) changes in the Substance manufacturing process; (c)
         changes in ORGANICS' manufacturing equipment; (d) manufacturing site
         changes; (e) changes in Substance specifications and/or test methods;
         and, (f) any Substance stability failures.

         ORGANICS further agrees, prior to amending any ORGANICS DMF that is
         referenced or contained in ENDEAVOR'S NDA, to provide reasonable
         advance written notice to ENDEAVOR, such that: (a) if such DMF
         amendment will require a supplement and/or amendment to the NDA that is
         subject to an FDA thirty (30) day notification period, then ORGANICS
         will provide no less than ninety (90) days' notice; (b) if such DMF
         amendment will require a supplement and/or amendment to the NDA that is
         subject to prior approval by FDA, then ORGANICS will provide sufficient
         notice to allow ENDEAVOR to obtain such prior approval.

         ENDEAVOR agrees to promptly notify ORGANICS, either itself or through
         its supplier of Delta, of all issues which, as defined by applicable
         GMPs and other FDA requirements, may impact the regulatory status of
         Substance, including but not limited to: (a) changes in the Delta
         manufacturing process; (b) changes in Delta manufacturing equipment;
         (c) manufacturing site

                                      -5-
<PAGE>

         changes; (d) changes in Delta specifications and/or test methods; and,
         (e) any Delta stability failures.

         The parties recognize that the extent to which GMPs are applicable to
         the production, storage and/or use of Substance and/or Product has
         evolved over time and continues to evolve as FDA modifies its positions
         on such applicability. With respect to Substance manufactured and/or
         delivered by ORGANICS to ENDEAVOR pursuant to this Agreement, the
         parties agree that compliance with GMPs will refer to those GMPs which
         are applicable to the manufacture of Substance, to be determined on a
         Batch-by-Batch basis as of the date of final quality control release by
         ORGANICS of each Batch. In the event of a dispute between the parties
         as to the applicability of GMPs, the decision of a mutually acceptable
         expert in GMP compliance, having signed a confidentiality agreement
         acceptable to ORGANICS, will be sought and shall be binding on the
         parties. The costs of the expert shall be borne by the non-prevailing
         party.

3.3      Alternative Source of Supply. ORGANICS shall use reasonable commercial
         efforts to identify a third party to act as an alternative source of
         supply for Substance to be provided hereunder to ENDEAVOR. Such third
         party shall be reasonably acceptable to and qualified by ENDEAVOR and
         shall supply Substance to ORGANICS and shall be subject to ORGANICS'
         quality assurance procedures. In such event, ORGANICS shall be under
         the same obligation as to pricing, quantities, quality, time
         constraints and other related supply matters as are provided herein for
         ORGANICS and ORGANICS shall guarantee performance of such third party.

3.4      Exclusive Sale. ORGANICS agrees that, subject to the provisions of
         Section 2.1 hereinabove, so long as ENDEAVOR is not in default pursuant
         to the terms and provisions of this Agreement and complies with the
         minimum annual purchases and/or fees provisions of Section 4.4
         hereinbelow, ORGANICS will not sell Synthetic Conjugated Estrogens APIs
         containing the Delta Component to any third party. In the event of a
         breach of this Agreement by ENDEAVOR which is not cured within the
         applicable time period specified in Section 8.2(a), or a failure by
         ENDEAVOR to comply with the minimum annual purchases and/or fees
         provisions set forth hereinafter in Section 4.4, then this provision of
         exclusivity shall no longer be applicable and ORGANICS, at its sole
         option, shall be free to sell or transfer Synthetic Conjugated
         Estrogens APIs containing the Delta Component to third parties for any
         use, without restriction and without affecting either party's remaining
         obligations hereunder, provided, however that, subject to the
         provisions of Section 2.1, ORGANICS shall not sell Synthetic Conjugated
         Estrogens containing the Delta Component to any third party for use or
         inclusion in any product intended to be filed as, or filed as, an
         Abbreviated New Drug Application referencing an ENDEAVOR Product NDA.

         In the event that ENDEAVOR provides notice to ORGANICS of its intention
         to terminate this Agreement under the provisions of Section 8.1 of this
         Agreement, upon receipt of such notice, ORGANICS shall have the
         irrevocable right to elect to seek out and develop markets for
         Synthetic Conjugated Estrogens APIs containing the Delta Component, and
         shall, for the last twelve (12) months of the period specified in
         Section 8.1 hereof, have the irrevocable right to sell Synthetic
         Conjugated Estrogens APIs containing the Delta Component to any third
         party for any use without restriction, which act(s) shall nor be deemed
         to be in breach or violation of this Agreement including, but not
         limited to, the first paragraph of this Section 3.4.

3.5      Other Estrogen Products. In the event ENDEAVOR decides to market any
         Estrogen Sulfate finished drug product other than Product, ENDEAVOR
         agrees to promptly notify ORGANICS thereof, and, within thirty (30)
         days of ENDEAVOR's notice, to give ORGANICS the opportunity to submit
         its bid for supplying the relevant APIs. In connection therewith,

                                      -6-
<PAGE>

3.6      ENDEAVOR agrees to promptly furnish ORGANICS with all relevant
         information in order to enable ORGANICS to submit said bid.

Article 4.        Orders, Shipment, Acceptance

4.1      Forecasts. Commitments, Purchase Orders. Subject to Section 4.2
         hereinbelow, on the quarterly schedule described in this Section 4.1,
         ENDEAVOR shall submit to ORGANICS its written forecasts of the
         quantities of Substance which ENDEAVOR expects to purchase in each of
         eight (8) consecutive Contract Quarters (hereinafter, cumulatively,
         "Planning Period"). The Forecast for the first of the eight ( 8 )
         Contract Quarters in any such Planning Period shall be deemed a firm
         commitment for which ENDEAVOR shall, subject to the provisions of
         Section 2.4, submit its purchase order(s) to ORGANICS; forecasts for
         the following seven (7) Contract Quarters in said Planning Period shall
         be considered as good faith estimates only, and shall not be binding on
         the parties. Each such quarterly submission shall update and revise
         previous Forecasts. ORGANICS shall notify ENDEAVOR promptly after
         receiving such forecasts and firm Commitments whether it anticipates an
         inability to supply the quantities of Substance specified in such
         forecasts and firm commitments.

         On a date which shall not be more than sixty (60) days in advance of
         the date on which purchase orders must be submitted, ORGANICS agrees to
         provide advance notice by facsimile to ENDEAVOR confirming the date by
         which ENDEAVOR'S forecasts and purchase orders are to be submitted to
         ORGANICS. ORGANICS further agrees to adjust said submission date as
         necessary to allow ENDEAVOR reasonable time to incorporate price
         increases, if any, in its purchase orders, as provided in Section 2.3
         of this Agreement. Unless so adjusted by ORGANICS, each such advance
         notice shall request that ENDEAVOR's forecast and its corresponding
         purchase order(s) be submitted at least one hundred ninety-five (195)
         days prior to the beginning of the Planning Period such that: (a) the
         forecast for the Planning Period beginning in January of any calendar
         year shall be submitted to ORGANICS by June 15th of the previous
         calendar year; (b) the forecast for the Planning Period beginning in
         April of any calendar year shall be submitted to ORGANICS by September
         15th of the previous calendar year; (c) the forecast for the Planning
         Period beginning in July of any calendar year shall be submitted to
         ORGANICS by December 15th of the previous calendar year; and (d) the
         forecast for the Planning Period beginning in October of any calendar
         year shall be submitted to ORGANICS by March 15th of that calendar
         year.

         ENDEAVOR agrees to forecast and order Substance in * increment
         quantities. ORGANICS agrees to accommodate ENDEAVOR'S requirements for
         Substance for each Contract Quarter, subject to the provisions set out
         in Section 4.2 hereinbelow and subject to the provisions of Article 6
         herein including, but not limited to, the timely receipt of Delta from
         ENDEAVOR. Upon receipt of ENDEAVOR'S purchase orders, which shall
         specify shipment dates not less than one hundred ninety-five (195) days
         nor more than two hundred eighty-five (285) days from the date of such
         purchase order, and any advance deposit required pursuant to Section
         2.4, ORGANICS shall place said purchase orders in its production
         schedule and set dates for shipment. These shipment dates shall be as
         close as reasonably possible to ENDEAVOR'S desired shipment dates. The
         acknowledgment of the purchase order shall be confirmed by ORGANICS in
         writing to ENDEAVOR.

4.2      Quantities. The total quantities of Substance ordered for delivery
         during any Contract Quarter shall be at least the quantity which
         ENDEAVOR committed to in its firm commitment. In the event that
         ENDEAVOR orders quantities of Substance which exceed by more than * the
         quantity

         * Certain information on this page has been omitted and filed
         separately with the Securities and Exchange Commission. Confidential
         treatment has been requested with respect to the omitted portions.

                                      -7-
<PAGE>

         forecasted in its firm commitment, ORGANICS shall have an additional *
         days to manufacture and ship such excess quantities.

4.3      Cancellation Policy. Notwithstanding the force majeure provisions of
         Section 10.1 hereinbelow, ENDEAVOR agrees that any purchase order
         issued to ORGANICS for Substance under this Agreement and acknowledged
         by ORGANICS in writing shall be deemed irrevocable. Accordingly, in the
         event that, for any reason unrelated to ORGANICS' ability to supply
         against such purchase order, ENDEAVOR requests cancellation of an
         acknowledged purchase order before manufacturing has begun, ORGANICS
         may, at its sole discretion, allow cancellation and assess ENDEAVOR a
         Cancellation fee in the amount of fifty percent (50%) of the invoice
         amount of the order, which fee shall be due and payable within thirty
         (30) days of the originally scheduled shipment date. If an advance
         deposit has been received with respect to such order, such advance
         deposit shall be treated as the cancellation fee. In the event that
         ENDEAVOR, subject to the provisions of Section 4.1, issues a new
         purchase order requesting delivery of an equal or greater amount of
         Substance within twelve (12) months of the originally scheduled
         shipment date, the full amount of the cancellation fee paid by ENDEAVOR
         shall be applied by ORGANICS toward payment of the invoice for the new
         order at the then applicable price. However, if no such shipment has
         been made within twelve (12) months following the originally scheduled
         shipment date of a canceled purchase order, provided that such failure
         is not due to any fault or failure of ORGANICS, the cancellation fee
         shall be deemed to be forfeited. In no case shall ENDEAVOR be permitted
         to cancel an acknowledged purchase order after manufacturing has begun.

4.4      Minimum Annual Purchases or Fees. Subject to the provisions of this
         Article 4, ENDEAVOR agrees that in each calendar year, beginning with
         calendar year 2000, it shall issue purchase orders for Substance to
         ORGANICS and/or shall remit the difference between the value of its
         purchase orders for the calendar year at the then current price and a
         minimum annual fee to be invoiced by ORGANICS such that: (a) for
         calendar year 2001, ENDEAVOR shall have taken delivery of a minimum of
         * of Substance or paid ORGANICS *; (b) for each of the calendar years
         2002 and 2003, ENDEAVOR shall have taken delivery of a minimum of * of
         Substance or paid ORGANICS the difference between the value of the
         actual quantity delivered in the calendar year and *; (c) for each of
         the calendar years 2004 and 2005, ENDEAVOR shall have taken delivery of
         a minimum of * of Substance or paid ORGANICS the difference between the
         value of the actual quantity delivered in the calendar year and *; (d)
         for calendar year 2006, ENDEAVOR shall have taken delivery of a minimum
         of * of Substance or paid ORGANICS the difference between the value of
         the actual quantity delivered in the calendar year and *; and, (e) for
         each calendar year beginning with calendar year 2007, ENDEAVOR shall
         have taken delivery of * or * of the previous calendar year's
         deliveries of Substance, in kilograms, whichever is the greater
         quantity.

         In the event that ENDEAVOR fails to take delivery of said minimum
         annual quantities and/or to remit said minimum fees, provided that such
         failure is not due to any fault or failure to supply by ORGANICS
         (including (i) ORGANICS' failure to deliver * of the quantity of
         Substance ordered pursuant to Section 4.5 below, or (ii) Substance that
         is appropriately rejected pursuant to Sections 4.7 and 4.8 below),
         then, as ORGANICS' exclusive remedy, the provision of exclusivity
         described in the first paragraph of Section 3.4 hereinabove shall no
         longer be applicable and ORGANICS, at its sole option, shall be free to
         sell or transfer Synthetic Conjugated Estrogens APIs containing the
         Delta Component, except as provided for in the first paragraph or
         Section 3.4, to any other party for any use without restriction and
         without affecting the remaining obligations hereunder.

         * Certain information on this page has been omitted and filed
         separately with the Securities and Exchange Commission. Confidential
         treatment has been requested with respect to the omitted portions.

                                      -8-
<PAGE>

4.5      Delivery, Shipment. ORGANICS agrees that, in executing purchase orders
         for Substance from ENDEAVOR, it will follow any reasonable
         specifications as to common carrier and shipping specifications. Actual
         delivery date shall be within ten (10) days of the confirmed and
         acknowledged delivery date. ORGANICS shall be deemed to have delivered
         adequate and appropriate quantity against ENDEAVOR'S purchase order if
         the quantity delivered is within ten percent (10%) of the quantity
         ordered.

4.6      Title Loss. In all sales of Substance, legal title and risk of loss
         shall pass from ORGANICS to ENDEAVOR at the point of delivery to a
         common carrier.

4.7      Samples, Acceptance, Rejection. ORGANICS shall not, except with
         ENDEAVOR'S express consent in writing, fulfill any orders placed by
         ENDEAVOR by shipping or delivering Substance without an accompanying
         certificate of analysis. Upon receipt of any shipment of Substance,
         ENDEAVOR shall determine if the specific delivery of Substance conforms
         to Specifications at the time of delivery, and shall notify ORGANICS of
         any analytical determination using validated methodology indicating
         failure to conform.

         If any shipment fails to conform to Specifications, ENDEAVOR shall
         promptly, but no later than twenty (20) business days after receipt of
         the specific de1ivery, notify ORGANICS that the shipment has failed to
         conform to Specifications; failure to notify ORGANICS within this
         period and/or proceeding with the manufacture of Product shall be
         deemed to be acceptance by ENDEAVOR of the shipment. ENDEAVOR's
         acceptance does not waive warranties. In the event that ENDEAVOR
         notifies ORGANICS of the rejection of any specific shipment of
         Substance, ENDEAVOR shall handle and store such Substance according to
         label requirements until ORGANICS has responded to the notice.
         ORGANICS, within thirty (30) days of receipt of the notice, may elect
         to have an agent inspect a sample of the rejected material, either at
         ENDEAVOR'S facility or at ORGANICS' facility. If there is any dispute
         between the parties, as to the acceptance or rejection of a shipment of
         Substance, such dispute shall be promptly resolved by having an
         ORGANICS' representative observe the performance of the inspection or
         analytical testing of the rejected material by ENDEAVOR, and should
         such dispute remain unresolved, by having a representative of ENDEAVOR
         observe the performance of the inspection or analytical testing by
         ORGANICS of ORGANICS' retained sample of the relevant Batch of
         Substance. If the discrepancy in observations or results cannot be
         resolved, then the inspection or testing shall be promptly performed on
         ORGANICS' retained sample, using ORGANICS' analytical methodology, by a
         mutually acceptable, qualified third party, having signed a
         confidentiality agreement acceptable to ORGANICS, who will resolve such
         dispute and such resolution shall be binding on both panics. In the
         event the third party's testing demonstrates that ENDEAVOR'S rejected
         material is out of Specification and ORGANICS' retained sample is
         within Specification, the parties agree to cooperate in good faith and
         establish a joint investigation team to determine the cause of the
         differing sample results. The investigation team will issue a report
         determining the cause of such discrepancy. The costs of the third party
         inspection or testing shall be done by the non-prevailing party.

4.8      Replacement. Subject to the provisions contained in Sections 4.7 and
         9.l(a) herein, rejected Substance shall be returned to the site
         designated by ORGANICS at ORGANICS' expense. The risk of loss for such
         returned Substance shall pass at the point of delivery to a common
         carrier and shall be borne by ORGANICS, provided that ENDEAVOR shall
         have given ORGANICS ten (10) days advance written notice of such
         return. ORGANICS shall, if it is responsible for non-compliance, use
         reasonable best efforts to replace any delivery of Substance rejected
         by ENDEAVOR as quickly as commercially practicable but in no event
         longer than two hundred

                                      -9-
<PAGE>

         forty (240) days, or refund any amounts paid by ENDEAVOR with respect
         to such shipment, at ENDEAVOR'S option.

4.9      Stability, Record Keeping, Inspection, etc. ORGANICS will: (a) select
         and retain samples of each Batch of Substance supplied hereunder and
         conduct an ongoing stability program in accordance with the provisions
         of the GMPs For APIs and ORGANICS' DMF (or any stability protocol
         mutually agreed to by the parties), and initiate and maintain all
         legally required documents and records including, without limitation,
         Batch and Lot production, and quality control and stability records
         capable of providing a complete and detailed manufacturing history,
         including the ability to trace all materials used by ORGANICS in the
         manufacture of Substance to their specific source by manufacturer's
         Batch or Lot control number, for such periods as are required by FDA;
         (b) conduct ongoing quality control and stability testing as provided
         in the applicable protocol and maintain such records; (c) furnish
         ENDEAVOR with copies of all Substance stability resting records at
         ENDEAVOR'S request; (d) at ENDEAVOR's option and upon reasonable notice
         to ORGANICS allow: (i) one (1) or more of ENDEAVOR's quality assurance
         employees or representatives to observe and inspect the non-proprietary
         manufacturing, packaging, testing, stability, and quality control
         facilities, records, and/or systems of ORGANICS which relate to
         Substance supplied hereunder for the purpose of determining compliance
         with the relevant GMPs; and (ii) a mutually acceptable, qualified third
         party chosen by ORGANICS and agreed to by ENDEAVOR, such agreement not
         to be unreasonably withheld, and who has signed a confidentiality
         agreement acceptable to ORGANICS, to inspect proprietary processes of
         ORGANICS which relate to Substance manufacturing by ORGANICS to
         determine compliance with the relevant GMPs, such inspection to be
         followed by an inspection by ENDEAVOR'S quality assurance personnel,
         having signed a confidentiality agreement acceptable to ORGANICS, only
         in the event that the third party finds critical defects and ORGANICS
         disagrees with such third party that remedial action is necessary, or
         disagrees with such third party as to whether or not the defect has
         been corrected (e) promptly inform ENDEAVOR of any actual or threatened
         legal or regulatory action or any actual inspection by FDA of ORGANICS'
         facilities or operations relating to Substance; and, (f) store, ship
         and dispose of all wastes generated as a result of its manufacture of
         Substance in accordance with all applicable laws and regulations.
         ENDEAVOR agrees that the results and observations made during any
         audits of ORGANICS conducted by or on behalf of ENDEAVOR in accordance
         with this Agreement are subject to the confidentiality provisions in
         Article 7 of this Agreement and will be supplied to ORGANICS in written
         form within sixty (60) days after such audit is completed.

4.10     Recall Procedure, Adverse Event Reporting, etc. IF ORGANICS learns of
         any information that might give rise to a recall or market withdrawal
         of Substance, then ORGANICS shall promptly provide notice thereof to
         ENDEAVOR. With respect to Product manufactured from Substance, any
         recall or market withdrawal shall be initiated at ENDEAVOR'S sole
         discretion, and ENDEAVOR shall be responsible for, and shall conduct,
         all interaction with FDA and other governmental authorities. To the
         extent possible under the circumstances, ENDEAVOR will inform ORGANICS
         simultaneous with informing FDA concerning any recall or market
         withdrawal of Product involving Substance. ORGANICS agrees to
         reasonably cooperate with ENDEAVOR in connection with any interactions
         or dealings with FDA, and to use reasonable best efforts to replace any
         Substance used in Product which has been recalled or withdrawn from the
         market due to a defect in such Substance, provided that such defect has
         been caused by ORGANICS' breach of its obligations under this
         Agreement, as soon as commercially practicable but not to exceed two
         hundred forty (240) days from written notification of ENDEAVOR's
         request for replacement.

                                      -10-
<PAGE>

Article 5.        Specifications, DMF, NDA Filing

5.1      Specifications. ORGANICS shall manufacture and supply Substance in
         accordance with the Specifications. The parties agree that neither
         party shall change the Specifications without the express written
         agreement of the other party. The parties further agree that if
         compendial or FDA requirements are changed and such changes require
         that the Specifications be modified to meet such changed compendial or
         FDA requirements, then the parties shall reasonably cooperate with each
         other to accomplish such modification with minimum disruption to the
         business interests of both parties. In the event that such
         modifications are required, ORGANICS shall: (a) follow the new
         requirements as soon as feasible with reasonable efforts; and, (b)
         except if otherwise agreed by the parties, provide ENDEAVOR the option
         to cancel, subject to the provisions of Section 4.3 of this Agreement,
         any purchase orders for Substance which are scheduled far manufacturing
         according to the previously relevant Specifications.

         Notwithstanding the provisions of Section 10.1 hereinbelow, ENDEAVOR
         shall purchase all such quantities of Substance meeting the previously
         relevant Specifications as ORGANICS has already started to produce, in
         whichever stage such production may be, according to ENDEAVOR'S firm
         orders; provided, however, if ENDEAVOR cannot use the Substance being
         produced, ORGANICS agrees to consult with ENDEAVOR and use commercially
         reasonable efforts to minimize costs to ENDEAVOR by taking actions to
         reduce ORGANICS' costs and pass any resulting savings on to ENDEAVOR.

5.2      DMF. ENDEAVOR expressly agrees that the manufacturing and control
         procedures and technology used by ORGANICS to manufacture Substance
         are, and shall remain, the property of ORGANICS, and are part of one or
         more ORGANICS' DMFs which are, and shall remain, the property of
         ORGANICS. ORGANICS agrees that so long as ENDEAVOR remains in
         compliance with the terms of this Agreement and so long as this
         Agreement remains in full force and effect, it will allow ENDEAVOR to
         reference the above mentioned DMFs for incorporation by reference of
         such parts thereof as may be required into ENDEAVOR'S NDA(s) for all
         Product derived from Substance under this Agreement. If this Agreement
         terminates in accordance with Article 8 hereof, ENDEAVOR may refer to
         such DMFs for a reasonable time, which shall not be less than the time
         required to sell sufficient Product to use inventory of Substance,
         provided it gives ORGANICS notice thereof.

Article 6.        Delta

6.1      ENDEAVOR Supply Obligations. ENDEAVOR shall supply sufficient
         quantities of Delta which meets the Delta Specifications and which is
         appropriate for use in manufacturing Substance to ORGANICS one hundred
         twenty (120) days in advance of the acknowledged shipment date of its
         purchase order(s). Accompanying each shipment of Delta, ENDEAVOR shall
         supply a certificate of analysis and shall advise ORGANICS of the value
         of such Delta for ORGANICS' use under Section 6.5. In the event
         ENDEAVOR fails to supply sufficient Delta in a timely manner, such
         failure shall relieve ORGANICS of its obligation(s) to supply hereunder
         to the extent of such failure.

6.2      Specifications for Delta. The parties agree that neither party shall
         change the Delta Specifications without the express written agreement
         of the other party.

6.3      Title; Risk of Loss. ENDEAVOR shall not charge, bill, or invoice
         ORGANICS for Delta when ORGANICS uses such Delta for compliance testing
         or in the manufacture of Substance. Legal

                                      -11-
<PAGE>

         title to Delta shall remain with ENDEAVOR while such Delta is in the
         possession or control of ORGANICS only until such time as the Delta is
         incorporated into ORGANICS' manufacturing process. Once incorporated
         into such process, legal title shall pass to ORGANICS. Should any
         Substance be rejected by ENDEAVOR subject to the provisions of Section
         4.7, then ORGANICS shall be responsible for the value of the Delta
         which value shall be the amount paid by ENDEAVOR to its supplier for
         the relevant receipt(s) of Delta.

6.4      Use of Delta. ORGANICS may not use Delta for any purpose other than
         production of Substance for ENDEAVOR, which production shall include
         reasonable analysis and testing of Delta as necessary to: (a) comply
         with applicable government regulations, including GMPs; and, (b)
         control or improve its synthesis or processing of Substance. ORGANICS
         may not assign or deliver possession of Delta to any third party except
         small quantities to recognized testing laboratories without ENDEAVOR'S
         prior consent.

6.5      Insurance. The value of the Delta for insurance purposes shall be the
         amount set forth in Exhibit D unless and until ORGANICS shall be
         advised otherwise by ENDEAVOR pursuant to Section 6.1. ORGANICS shall
         be responsible to maintain property insurance coverage to protect the
         replacement value of Delta on a special perils basis, subject to a
         $1,000 deductible, on the inventory that is in its care, custody and
         control. In the event of destruction, loss, or damage then ORGANICS'
         liability to ENDEAVOR shall be limited to the lesser of the amount paid
         by ENDEAVOR to its supplier for such Delta or the amount set forth in
         Exhibit D.

Article 7.        Confidentiality

7.1      Confidential Information. It is acknowledged that the implementation of
         this Agreement, as well as the operations of the parties prior to
         execution of this Agreement will result and has resulted, in a
         continuous exchange of information and data as a result of which each
         of the companies will and has become more knowledgeable about the
         business and operations of the other as well as knowledgeable as to
         many material aspects involved in the manufacture and production of
         Substance, Product, product research and development, and Conjugated
         Estrogens and its finished products. Such information and data is
         herein referred to as "Confidential Information." In order to protect
         the business interests, trade secrets, and all areas deemed
         confidential by both parties hereto, the parties warrant and represent
         that they have kept and maintained as confidential, and agree in the
         future to so keep and maintain each other's Confidential Information,
         and agree as follows:

         (a)      ENDEAVOR expressly agrees that all data, information and
                  knowledge received by ENDEAVOR from ORGANICS relative to the
                  business, operations, customers, sales, distribution, or
                  suppliers, and/or to the manufacture, formulation or
                  production of Conjugated Estrogens and/or other Estrogen
                  Sulfates, whether Substance or other APIs, shall be deemed the
                  Confidential Information of ORGANICS. Such Confidential
                  Information of ORGANICS shall include that specifically
                  revealed to ENDEAVOR by ORGANICS, as well as that acquired by
                  ENDEAVOR through its observations, investigations and
                  activities within the facilities of ORGANICS and also that
                  acquired by ENDEAVOR from its patent counsel regarding
                  ORGANICS' process for the synthesis of Substance. ENDEAVOR
                  shall not disclose any Confidential Information of ORGANICS to
                  any third party, nor shall ENDEAVOR use the Confidential
                  Information of ORGANICS except for purposes provided for in
                  this Agreement, or necessary to carry out the provisions of
                  this Agreement. Specifically, all intellectual property,
                  whether patented or not, trade secrets and know-how on the
                  structure and formulation of

                                      -12-
<PAGE>

                  Substance and/or any other Estrogen Sulfate API, all items
                  which contribute to the formulation of the key intermediates
                  which are used to manufacture Substance, the stability
                  thereof, techniques, evaluations, the formulations and related
                  methods, know-how, data, design, formulas, compositions,
                  specifications, compounds, materials, processes, discoveries,
                  equipment, machines, inventions, trade secrets, methods,
                  steps, procedures and/or computer programs related to the
                  technology or methodology involved in the development,
                  manufacture or production of Substance or other Estrogen
                  Sulfate APIs, disclosed to ENDEAVOR by ORGANICS are and shall
                  remain the property of ORGANICS and shall be deemed
                  Confidential Information of ORGANICS as herein defined.

         (b)      ORGANICS expressly agrees that all data information and
                  knowledge received by ORGANICS from ENDEAVOR relative to the
                  business, operations, customers, sales, distribution, or
                  suppliers, and/or to the manufacture, formulation or
                  production of its Products, whether utilizing Substance or
                  other APIs, shall be deemed the Confidential Information of
                  ENDEAVOR. Such Confidential Information of ENDEAVOR shall
                  include that specifically revealed to ORGANICS by ENDEAVOR, as
                  well as that acquired by ORGANICS through its observations,
                  investigations and activities within the facilities of
                  ENDEAVOR and also that acquired by ORGANICS or ORGANICS' legal
                  counsel regarding ENDEAVOR'S intellectual property. ORGANICS
                  shall not disclose any Confidential Information of ENDEAVOR to
                  any third party, nor shall ORGANICS use the Confidential
                  Information of ENDEAVOR except for purposes provided for in
                  this Agreement, or necessary to carry out the provisions of
                  this Agreement. Specifically, all intellectual property,
                  whether patented or not, trade secrets, and know-how relating
                  to the Products, Products' API, research and development
                  projects relating to new products, the stability thereof,
                  techniques, evaluations, the formulations and related methods,
                  know-how, data, design, formulas, compositions,
                  specifications, compounds, materials, processes, discoveries,
                  equipment, machines, inventions, trade secrets, methods,
                  steps, procedures and/or computer programs related to the
                  technology or methodology involved in the development,
                  manufacture or production of Products or research and
                  development projects relating to new products, disclosed to
                  ORGANICS by ENDEAVOR are and shall remain the property of
                  ENDEAVOR and shall be deemed Confidential Information of
                  ENDEAVOR as herein defined.

7.2      Obligation of Confidentiality. The obligation of confidentiality
         imposed by this Article 7 shall not apply to information which the
         receiving party can show in writing: (a) was in its possession prior to
         receipt from the disclosing party; (b) is now or hereafter comes into
         the public domain through no fault or the receiving party; (c) is
         acquired from a third party who is not obligated under an agreement of
         confidentiality to the disclosing party; (d) was subsequently developed
         independent of the disclosure; or (e) is required by law or regulations
         of federal or state governmental agencies to be disclosed.

         At the conclusion of this Agreement, by termination, expiration or
         otherwise, each party agrees to return forthwith all Confidential
         Information, including documents and computer files, and all copies
         thereof, disclosed by each party to the other except as required to be
         maintained by applicable governmental regulations, in which case the
         party so retaining such Confidential Information shall retain it only
         for the purposes so required by such governmental regulations. This
         confidentiality obligation shall survive the termination or expiration
         of this Agreement for any reason for a period of ten (10) years from
         the effective date thereof, or so long as the information continues to
         be deemed confidential by the original discloser, whichever is longer.
         The determination that the information continues to be deemed
         confidential shall be the sole

                                      -13-
<PAGE>

         prerogative of the original disclosing party, which shall be set forth
         in a written response to the receiving party upon written request by
         said party. The receiving party agrees to limit disclosure of the
         information imparted by the disclosing party to only those of its
         officers, agents and representatives as are necessary to carry out the
         purposes of this Agreement, and only to the extent reasonably necessary
         in accordance therewith, and, in each such instance, the receiving
         party shall require said individual(s) or companies to execute a
         confidentiality agreement requiring the same degree of confidentiality
         undertaken by this Article 7.

Article 8.        Term, Termination, Survival

8.1      Term. The Term of this Agreement shall commence on the later of the
         execution dates set forth at the end of this Agreement and shall
         continue in effect until terminated by one of the parties by providing
         written notice of such termination to the other party in accordance
         with this Article 8. Either party may terminate this Agreement without
         cause by notifying the other party of its intention to terminate
         thirty-six (36) months in advance of the effective date of said
         termination, provided, however, that neither party shall provide such
         notice prior to the seventh (7th) anniversary of the date of this
         Agreement.

8.2      Termination by ORGANICS. ORGANICS shall have the right to terminate
         this Agreement upon written notice to ENDEAVOR if any of the following
         events occur:

         (a)      Material default shall be made by ENDEAVOR in the due
                  observance or performance of any warranty, covenant or
                  agreement of ENDEAVOR hereunder, and such default shall not
                  have been cured (i) in the event of non-payment by ENDEAVOR
                  within five ( 5 ) business days after receipt of written or
                  Facsimile notice thereof from ORGANICS and (ii) other than
                  that due to force majeure as outlined in Section 10.1 of this
                  Agreement, in all other events within sixty (60) days after
                  receipt of written notice thereof from ORGANICS. Provided that
                  written or facsimile notice has been given, in the event of
                  non-payment or a default in the performance of Section 9.8.
                  ORGANICS may, at its sole discretion, delay shipment and/or
                  cancel any or all existing acknowledged purchase orders and
                  refuse to accept new orders, which actions shall not
                  constitute a breach of this agreement by ORGANICS. Anything in
                  this Section 8.2(a) to the contrary notwithstanding, ORGANICS
                  may terminate this agreement immediately, upon written notice,
                  in the event of a default by ENDEAVOR in the performance of
                  Section 9.8.

         (b)      ENDEAVOR is declared insolvent or bankrupt by any court of
                  competent jurisdiction, or a voluntary petition of bankruptcy
                  or the equivalent thereof is filed in any court of competent
                  jurisdiction by ENDEAVOR, or an, involuntary petition of
                  bankruptcy (or the equivalent thereof) is filed in any court
                  of competent jurisdiction against ENDEAVOR, and within
                  forty-five (45) days thereafter shall not have been dismissed
                  or stayed (or in the event of any such stay, such stay shall
                  not thereafter have been set aside within forty-five (45)
                  days).

         (c)      ENDEAVOR makes or executes an assignment for the benefit of
                  creditors or the equivalent.

         (d)      ENDEAVOR violates its obligations under Section 3.1 of this
                  Agreement.

         (e)      ENDEAVOR fails to file an NDA application for Product by
                  December 31,2002, such application is not approved by December
                  31,2004, ENDEAVOR fails to begin marketing

                                      -14-
<PAGE>

                  of a Product by June 30, 2005, ENDEAVOR withdraws its NDA
                  application for all Products, or ENDEAVOR fails to place a
                  purchase order with ORGANICS for Product during any eighteen
                  (18) month period.

8.3      Termination by ENDEAVOR. ENDEAVOR shall have the right to terminate
         this Agreement upon written notice to ORGANICS if any of the following
         events occurs:

         (a)      Material default shall be made by ORGANICS in the due
                  observance or performance of any warranty, covenant or
                  agreement of ORGANICS hereunder, other than that due to force
                  majeure as outlined in Section 10.1 of this Agreement. and
                  such default shall not have been cured within sixty (60) days
                  after receipt of written notice thereof from ENDEAVOR. The
                  parties agree that ORGANICS shall not be considered to be in
                  material default for failing to supply Substance to ENDEAVOR
                  if the DMF for Delta is deficient and such deficiency is the
                  cause of the default.

         (b)      ORGANICS is declared insolvent or bankrupt by any court of
                  competent jurisdiction, or a voluntary petition of bankruptcy
                  or the equivalent thereof is filed in any court of competent
                  jurisdiction by ORGANICS, or an involuntary petition of
                  bankruptcy (or the equivalent thereof) is filed in any court
                  of competent jurisdiction against ORGANICS, and within
                  forty-five (45) days thereafter shall not have been dismissed
                  or stayed (or in the event of any such stay, such stay shall
                  not thereafter have been set aside within forty-five (45)
                  days).

         (c)      ORGANICS makes or executes an assignment for the benefit of
                  creditors or the equivalent.

8.4      Effect of Termination, Survival. The termination of this Agreement by
         either party pursuant to this Article 8 shall not bar the party
         terminating the Agreement from pursuing any and all of its other legal
         and equitable remedies against the other party including, without
         limitation, monetary damages for breach of contract. Such termination
         shall not release either party from any obligations hereunder, nor
         shall it affect the various representations, warranties, and agreements
         provided in Articles 9 and 10, inter alia, which are intended and shall
         be deemed to survive such termination.

8.5      Negotiation and Mediation Prior to Termination in Certain Cases. Prior
         to the service of notice of termination by ORGANICS for any reason
         other than non-payment by ENDEAVOR or termination based upon Sections
         8.2(b), 8.2(c) or 9.8 hereof, and prior to the service of notice of
         termination by ENDEAVOR for any reason other than termination based
         upon Section 8.3(b) or (c) hereof, the parties shall attempt to resolve
         any dispute contributing or relating to grounds for termination by
         mediation under the then current CPR Mediation Procedure. Unless
         otherwise agreed, the parties shall select a mediator from the CPR
         Panels of Distinguished Neutrals. If such dispute has not been resolved
         within thirty (30) days of the initiation of such procedure, the party
         or parties desiring to serve such notice of termination may do so.

Article 9.        Warranty; Indemnity

9.1      ORGANICS Warranty. ORGANICS makes the following limited warranties with
         respect to all Substance delivered to ENDEAVOR under this Agreement:
         (a) that Substance shall (i) conform

                                      -15-
<PAGE>

         to applicable GMPs, the applicable ORGANICS DMF and the Specifications
         at the time of shipment, and shall conform to the stability commitments
         contained in ORGANICS' DMF or otherwise provided by ORGANICS to FDA;
         and, (ii) no article delivered to ENDEAVOR shall be adulterated or
         misbranded within the meaning of the United States Federal Food, Drug
         and Cosmetic Act, or be an article which may not, under the provisions
         of Sections 404 and 505 of the Act, be introduced into interstate
         commerce; and, (b) that ORGANICS shall comply with applicable GMPs in
         the production of Substance, including additions and amendments to such
         regulations during the Term of this Agreement; and, (c) that ORGANICS
         shall comply with all other material statutes and regulations
         applicable to the manufacture and supply of Substance at the time of
         production, storage, and shipment including, without limitation, those
         relating to the generation, storage, shipment and disposal of waste;
         and, (d) that ORGANICS has all right, title and interest in and to the
         technology and processes used to produce Substance and that its
         production of Substance shall not infringe a patent or the intellectual
         property rights of any third party *.

         ENDEAVOR expressly agrees that ENDEAVOR and/or any other parties
         involved in the formulation, manufacturing and distribution of Product
         are solely responsible for Product stability and that ORGANICS'
         warranty obligations with respect to stability extend solely to
         Substance.

         In no event does ORGANICS warrant that Substance will meet
         Specifications after its labeled re-evaluation date has passed and,
         under such circumstances, ORGANICS will neither replace Substance nor
         refund the amount paid by ENDEAVOR. Except where the provisions of
         Section 4.7 apply, in the event that ENDEAVOR and ORGANICS disagree
         with respect to the current potency of Substance under this warranty,
         then ORGANICS' analysis of ORGANICS' retained stability sample of the
         specific Batch of Substance in question shall be the sole determination
         of the potency of Substance. Analytical data generated by ORGANICS in
         connection with a claim under this warranty shall be supplied to
         ENDEAVOR upon request. Notwithstanding the above, ORGANICS will not and
         does not warrant that Substance will meet Specifications if ENDEAVOR or
         its agents and/or its Contract Manufacturer has not stored and/or
         handled such Substance according to labeling, and in compliance with
         relevant GMPs. These limited warranties are extended to ENDEAVOR and
         shall not be assignable, transferable, or extended to any other party
         except under the provisions of Section 10.3 herein.

         IN NO EVENT SHALL ANY ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY
         ORGANICS, ITS EMPLOYEES, DISTRIBUTORS, DEALERS OR AGENTS INCREASE THE
         SCOPE OF THE WARRANTIES IN THIS AGREEMENT OR CREATE ANY NEW WARRANTIES
         HEREUNDER. THESE LIMITED WARRANTIES ARE EXCLUSIVE AND IN LIEU OF ALL
         OTHER WARRANTIES, INCLUDING THE IMPLIED WARRANTIES OF MERCHANTABILITY
         AND FITNESS FOR A PARTICULAR PURPOSE. ALL OTHER WARRANTIES, BOTH
         EXPRESS AND IMPLIED, ARE HEREBY EXPRESSLY EXCLUDED.

9.2      ENDEAVOR Warranty. ENDEAVOR makes the following warranties: (a) that
         Delta delivered to ORGANICS hereunder shall comply with the Delta
         Specifications; (b) that no article delivered hereunder to ORGANICS by
         or on behalf of ENDEAVOR shall be adulterated or misbranded within the
         meaning of the United States Federal Food, Drug and Cosmetic Act, or be
         an article which may not, under the provisions of Sections 404 and 505
         of the Act, be introduced into interstate commerce; (c) that the
         manufacture and supply of Product and the manufacture and supply of
         Delta will be in compliance with applicable GMPs and any other
         applicable FDA requirements and all applicable Local or national laws,
         rules and regulations governing the use and storage of Substance and
         the manufacture, use and storage of Product; and, (d) that

* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                                      -16-
<PAGE>

         ENDEAVOR has the right to provide Delta to ORGANICS and that: (i) the
         manufacture, importation, use, transfer, or sale of Delta and/or the
         use of Delta and/or its salts or esters in the processing, production
         or formulation of Substance; and, (ii) the formulation, sale or
         distribution of my Product containing Substance, do not infringe any
         patent *.

9.3      Reciprocal Warranty and Representation Regarding Debarment. Each party
         warrants and represents to the other that none of its employees,
         officers, directors or agents has been: (a) debarred, or convicted of a
         crime for which a person can be debarred, under section 306(a) of the
         U.S. Federal Generic Drug Enforcement Act of 1992, as amended; or, (b)
         knowingly threatened with debarment or indictment for such a crime. If
         any such debarment or conviction occurs while this Agreement is in
         force and effect, then the party involved with such debarment or
         conviction shall promptly provide written notification to the other
         party.

9.4      ORGANICS Indemnification for Claims other than Parent Infringement.
         Except for Claims alleging patent infringement, ORGANICS will indemnify
         and hold harmless ENDEAVOR and its officers, directors and employees
         against any loss, damage, action, suit, claim, demand, prosecution,
         liability or expense, including reasonable attorney's fee and costs
         (all referred to hereinafter in Article 9 as "Claim") that may be
         brought, instituted or arise against or be incurred by ENDEAVOR or any
         such officer, director or employee which involves or is related to
         Substance (including, without limitation, product liability Claims)
         only if and to the extent such Claim is based on or arises out of: (a)
         ORGANICS' failure to manufacture and supply Substance in accordance
         with the Specifications; or, (b) the failure of any Substance supplied
         by ORGANICS to comply with the warranty described in Section 9.l(a),
         (b) or (c) herein.

         In the event that any Product manufactured by or on behalf of ENDEAVOR
         from Substance is recalled from the market then all of the expenses
         attendant thereto, including, without limitation, shipping, insurance,
         loss of profit, credits, returns, rebates, and any other costs
         incidental or consequential thereto, shall be the sole responsibility
         of ENDEAVOR unless the cause of such recall, which shall be established
         by independent and competent authority, is shown to be due to the
         failure of any Batch of substance used in the recalled Product to
         comply with the warranty described in Section 9.l(a), (b) or (c) of
         this Agreement. In such event, ORGANICS indemnification of ENDEAVOR for
         such recall costs shall be limited to the value or cost of Substance
         and ENDEAVOR'S out-of-pocket costs for direct labor and materials used
         in the recalled Product.

9.5      ENDEAVOR Indemnification for Claims other than Patent Infringement.
         Except for Claims alleging patent infringement, ENDEAVOR will indemnify
         and hold harmless ORGANICS and its officers, directors and employees
         against any Claim that may be brought, instituted or arise against or
         be incurred by ORGANICS or any such officer, director or employee which
         involves or is related to Product (including, without limitation,
         product liability Claims) only if and to the extent such Claim is based
         on or arises out of the use or transfer by ENDEAVOR or any ENDEAVOR
         Contract Manufacturer, distributor or Co-marketer, of Substance, or
         arises out of the manufacture, supply, use, transfer and/or sale of
         Product by, for, or on behalf of ENDEAVOR or any ENDEAVOR distributor
         or Co-marketer, including, without limitation, any investigation by a
         government agency, or any Claim for personal injury or property damage
         asserted by any user of such Product, except in each case to the extent
         such Claim is based on or arises out of: (a) ORGANICS' failure to
         manufacture and supply Substance in accordance with the Specifications;
         or (b) the failure of any Substance supplied by ORGANICS to comply with
         the warranty described in Section 9.l(a), (b) or (c) herein.

* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                                      -17-
<PAGE>

9.6      ORGANICS Indemnification for Claims of Patent Infringement. If any
         third party institutes a Claim against ENDEAVOR which is based upon a
         breach of the warranty contained in Section 9.l(d) then ORGANICS will
         indemnify and hold harmless ENDEAVOR and its officers, directors and
         employees against any such Claim that may be brought, instituted or
         arise against, or be incurred by ENDEAVOR or any such officer, director
         or employee.

9.7      ENDEAVOR Indemnification For Claims of Patent Infringement. If any
         third party institutes a Claim against ORGANICS which is based upon a
         breach of the warranty contained in Section 9.2(d) then ENDEAVOR shall
         indemnify and hold harmless ORGANICS and its officers, directors and
         employees against any such Claim that may be brought, instituted or
         arise against, or be incurred by ORGANICS or any such officer, director
         or employee. This indemnification as it applies to Delta shall not
         apply in the event that ORGANICS changes the Substance synthesis
         process as it relates to Delta so that the actual process utilized is
         different from that contained in the sealed archived copy of the
         process retained by ENDEAVOR patent counsel under a separate agreement.

9.8      Funding of Obligations under Section 9.7.

         (a)      On or before October 1, 2001, or such later date to which
                  ORGANICS may consent in writing, ENDEAVOR shall establish a
                  separate bank account (the "Account") which shall be
                  maintained until the end of the thirty-sixth (36th)
                  month-following the date (the "Introduction Date") on which
                  the first (1st) Product is sold in the United States pursuant
                  to an approved NDA.

         (b)      ENDEAVOR shall maintain the following balances in the Account
                  less any amounts actually paid to fulfill its obligations
                  under Section 9.7 hereof:

----- ------------------------------------------------------------------ -------
                                  Time Period                            Balance
----- ------------------------------------------------------------------ -------
      For the period beginning on October 1, 2001 and ending on the         *
      earlier of (i) the date on which an NDA for a Product is approved;
      (ii) the date on which ENDEAVOR issues its first press release or
      public comment regarding the first Product; (iii) the date on
      which a suit is filed which suit includes a claim based upon a
      breach of warranty contained in Section 9.2(d); or, (iv) the date
      of a public threat of the filing of a suit which would include a
      claim based upon a breach of warranty contained in Section 9.2(d)
      (the earliest date under (i), (ii), (iii) or (iv) above referred
      to as the "Public Date").
----- ------------------------------------------------------------------ -------
      For the period beginning on the Public Date and ending on             *
      the date  twelve (12) months after the Introduction Date.
----- ------------------------------------------------------------------ -------
      For the period beginning twelve (12) months after the                 *
      Introduction Date and ending twenty-four (24) months after
      the Introduction Date.
----- ------------------------------------------------------------------ -------
      For the period beginning twenty-four (24) months after the            *
      Introduction Date and ending thirty-six (36) months after
      the Introduction Date.
----- ------------------------------------------------------------------ -------

* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

                                      -18-
<PAGE>

         (c)      ENDEAVOR shall make appropriate arrangements with the bank at
                  which the Account is maintained to permit the President and
                  the Chief Financial Officer of ORGANICS to make independent
                  balance inquiries regarding the Account at any time or times
                  during normal business hours desired by such officer of
                  ORGANICS.

         (d)      ENDEAVOR shall use any funds required to be maintained in the
                  Account solely for the purpose of fulfilling its obligations
                  under Section 9.7 hereof.

         (e)      The Account balances provided for in Section (b) above shall
                  not be interpreted as a limit on ENDEAVOR's obligations
                  pursuant to Section 9.7 hereof.

9.9      Assertion of Claims.

         (a)      Each indemnified party agrees to give the indemnifying party
                  prompt written notice of any Claim or discovery of fact upon
                  which such indemnified party intends to base a request for
                  indemnification under Sections 9.4, 9.5, 9.6 or 9.7 of this
                  Agreement.

         (b)      Each party shall furnish promptly to the other, copies of all
                  papers and official documents received in respect of any
                  Claim. The indemnified party will cooperate with the
                  indemnifying party in providing witnesses and records
                  necessary in the defense against any Claim under appropriate
                  confidentiality agreements,

         (c)      With respect to any Claim relating solely to the payment of
                  money damages and which will not result in the indemnified
                  party becoming subject to injunctive or other relief, and as
                  to which the indemnifying party shall have acknowledged in
                  writing the obligation to indemnify the indemnified party
                  hereunder, the indemnifying party shall have the sole right to
                  defend, settle or otherwise dispose of such Claim on such
                  terms as the indemnifying party, in its sole discretion, shall
                  deem appropriate.

         (d)      The indemnifying party shall obtain the written consent of the
                  indemnified party, which shall not be unreasonably withheld,
                  prior to ceasing to defend, settling or otherwise disposing of
                  any Claim if as a result thereof the indemnified party would
                  become subject to injunctive or other equitable relief or any
                  remedy other than the payment of money, which payment would be
                  the responsibility of the indemnifying party.

         (e)      The indemnifying party shall not be liable for any settlement
                  or other disposition of a Claim by the indemnified party which
                  is reached without the written consent of the indemnifying
                  party.

         (f)      Except as provided above, the reasonable costs and expenses,
                  including reasonable fees and disbursements of counsel
                  incurred by any indemnified party in connection with any
                  Claim, shall be reimbursed on a quarterly basis by the
                  indemnifying party, without prejudice to the indemnifying
                  party's right to contest the indemnified party's right to
                  indemnification and subject to refund in the event the
                  indemnifying party is ultimately held not to be obligated to
                  indemnify the indemnified party.

9.10     Third Party License. Nothing in this Agreement shall prevent ORGANICS
         or ENDEAVOR, in either case solely at its own expense, from obtaining a
         license or other rights from any third party that ORGANICS or ENDEAVOR,
         as the case may be, deems appropriate in order to permit it the full
         and unhindered exercise of the making, using, or selling of Substance
         or Product, as the case

                                      -19-
<PAGE>
         may be. The party seeking to obtain such license or other rights from a
         third party shall promptly notify the other party in writing of its
         intention to do so.

Article 10.       Miscellaneous

10.1     Force Majeure. If the performance of any obligation under this
         Agreement by either party is prevented, restricted, interfered with or
         delayed, either directly or indirectly, by reasons of any cause beyond
         the reasonable control of the party required to perform, including, but
         not limited to: adverse weather conditions, fire, flood, acts of God,
         accidents, explosions, strikes or other labor disturbances, civil
         commotions, riots, rebellions, wars or restraints, requisitions, new
         regulations or directions of the United States or other relevant
         government, mandatory compliance by ORGANICS or ENDEAVOR with any
         request of such government, or any officer, department, agency or
         committed thereof that represents a change in policy or a new
         undertaking, or shortages of or inability to obtain fuel or power, or
         inability to obtain or delay in transportation facilities, unless
         conclusive evidence to the contrary is provided, the party so affected
         shall, upon giving prompt written notice to the other party (including
         a full description of particulars), be excused From such performance
         and shall not be deemed to be in breach of this Agreement to the extent
         and duration of such prevention, restriction, interference or delay
         provided that the affected party shall use its reasonable best efforts
         to avoid or remove such causes of non performance and shall continue
         performance with the utmost dispatch whenever such causes are removed.

         If the Force Majeure in question prevails for a continuous period in
         excess of six (6) months, the parties shall enter into bona fide
         discussions with a view to alleviating its effects or to agreeing upon
         such alternative arrangements as may be fair and reasonable.

10.2     Notices. All notices given under this Agreement shall be in writing and
         shall be personally delivered by a reputable express delivery service
         or mailed by certified first class mail, return receipt requested, to
         the party for which it is intended at its address as set forth below,
         or at such other address as the addressee may have designated to the
         other party in writing. Any notice shall be deemed given only upon
         actual delivery thereof at the proper address. Routine correspondence
         may be transmitted by telefax machine and confirmed by the sender's
         telefax machine of the recipient's telefax machine number set forth
         below.

         All notices to ORGANICS, other than routine correspondence relating to
         and including purchase orders, forecasts, invoices and revisions shall
         be addressed to:

                Attention:                Lois K. Kicks
                                          President
                                          ORGANICS/LaGrange, Inc.
                                          1935 Techny Road, Suite 14
                                          Northbrook, IL  60062

                With a copy to:           Lael F. Johnson
                                          Schiff Hardin & Waite
                                          6600 Sears Tower
                                          Chicago, Illinois 60606

         Routine correspondence relating to and including purchase orders,
         forecasts and revisions to ORGANICS shall be addressed to:

                                      -20-
<PAGE>

                Attention:                Sales Department
                                          ORGANICS/LaGrange, Inc.
                                          1935 Techny Road, Suite 14
                                          Northbrook, IL 60062
                                          Telefax 847-480-1801

         All notices to ENDEAVOR other than routine correspondence relating to
         and including purchase orders, forecasts and revisions shall be
         addressed to:

                Attention:                R. Forrest Waldon
                                          President and Chief Executive Officer
                                          Endeavor Pharmaceuticals, Inc.
                                          127 Racine Drive, Suite 202
                                          Wilmington, NC 28403

                With a copy addressed to:

                Attention:                CHIEF FINANCIAL OFFICER
                                          Endeavor Pharmaceuticals, Inc.
                                          127 Racine Drive, Suite 202
                                          Wilmington, NC 28403

         Routine correspondence addressed to ENDEAVOR relating to and including
         purchase orders, forecasts, and revisions shall be addressed to:

                Attention:                Angela Davis
                                          Associate Director, Project Management
                                          Endeavor Pharmaceuticals, Inc.
                                          127 Racine Drive, Suite 202
                                          Wilmington, NC 28403
                                          Telefax 910-790-9041

         Either party may notify the other party from time to time of any change
         of address for notices required by this Agreement.

10.3     Assignment. This Agreement shall not be assignable in whole or in part
         by either party without the prior written consent of the other party,
         except that either party may assign this Agreement to a successor in
         interest which succeeds to such interest by merger, consolidation, or
         purchase of all or substantially all of the assets of the party, or the
         sale of all or substantially all of a party's business dedicated to the
         Product(s).

10.4     Superiority of Agreement and Amendments. The parties agree that the
         provisions of this Agreement, together with any amendments thereto
         shall constitute the full and complete agreement by and between the
         parties and shall prevail over any inconsistent previous
         understandings. This Agreement may not be changed, waived, discharged
         or terminated orally, but only by an instrument in writing signed by
         the party against which enforcement of such change, waiver, discharge
         or termination is sought. The parties also agree that the provisions of
         this Agreement together with any amendments adopted under the
         provisions of this Section 10.4 shall be superior to and prevail over
         any conflicting provisions contained in any purchase order,
         acknowledgment, or confirmation.

                                      -21-
<PAGE>

10.5     Waiver. No waiver by any party hereto or any breach or anticipated
         breach of any provision hereof by the other party shall be deemed a
         waiver of any other contemporaneous, preceding or succeeding breach or
         anticipated breach, whether or not similar.

10.6     Law Governing, etc. This Agreement shall be governed and construed in
         accordance with the laws of the State of Illinois except for its choice
         of law provisions.

10.7     Negation of Agency. Nothing herein contained shall be deemed to create
         an agency, joint venture, amalgamation, partnership, or similar
         relationship between ORGANICS and ENDEAVOR.

10.8     Counterparts. This Agreement may be executed simultaneously in several
         counterparts, each of which shall be deemed an original, but all of
         which together shall constitute one and the same instrument.

10.9     Severability.

         (a)      If any of the terms of this Agreement; not material to the
                  remaining portions hereof, shall be held illegal, void or
                  ineffective, the remaining terms hereof shall remain in full
                  force and effect.

         (b)      If any of the terms of this Agreement are in conflict with any
                  applicable statute or rule of law, then such terms shall be
                  deemed inoperative to the extent that they may conflict
                  therewith and shall be deemed to be modified to conform with
                  such statute or rule of law.

         (c)      In the event that the terms of this Agreement are materially
                  altered as a result of Sections 10.9 (a) or (b), the parties
                  shall in good faith re-negotiate the terms and conditions of
                  this Agreement to resolve any inequities.

10.10    Headings. Underlined Article, Section and/or paragraph headings
         contained in this Agreement are included for convenience only and form
         no part of this Agreement.

10.11    Publicity. No public announcement concerning the existence or the terms
         of this Agreement shall be made, either directly or indirectly, by
         either party to this Agreement, except as may be legally required by
         law or judicial order, without first obtaining the written approval of
         the other party and agreement upon the nature, text and timing of such
         announcement, which approval and agreement shall not be unreasonably
         withheld. The party desiring to make any such public announcement shall
         provide the other party with a written copy of the proposed
         announcement in reasonably sufficient time prior to public release to
         allow such other party to comment upon such announcement prior to
         public release and to allow the first party to incorporate any
         suggested changes into such announcement. ENDEAVOR shall not issue any
         press release or make any public announcement which includes the name
         "ORGANICS" or "ORGANICS/LaGrange, Inc.," or otherwise uses the name
         "ORGANICS" or "ORGANICS/LaGrange, Inc." in any statement or document
         (except between the parties hereto) except with the prior written
         consent of ORGANICS. ORGANICS shall not issue any press release or make
         any public announcement which includes the name "ENDEAVOR" or "ENDEAVOR
         PHARMACEUTICALS, Inc." or otherwise uses the name "ENDEAVOR" or
         "ENDEAVOR PHARMACEUTICALS, Inc." in any statement or document (except
         between the parties hereto) except with the prior written consent of
         ENDEAVOR.

                                      -22-
<PAGE>

         If ENDEAVOR concludes that this Agreement must be filed with the
         Securities and Exchange Commission or any other securities regulatory
         agency, ENDEAVOR shall give written notice to ORGANICS as far in
         advance prior to such filing as reasonably possible and shall give
         reasonable consideration to the advice and suggestions of ORGANICS
         regarding the portion or portions of such Agreement or exhibits thereto
         as to which confidential treatment will be requested. ENDEAVOR shall
         give ORGANICS advance notice of the expiration of confidential
         treatment granted by the Securities and Exchange Commission with
         respect to any portion or portions of this Agreement and shall give
         reasonable consideration to the advice and suggestions of ORGANICS
         regarding a request for extensions of such period of confidential
         treatment. ENDEAVOR and ORGANICS agree that each of them shall, in the
         conduct of their business, treat as confidential any portion or
         portions of this Agreement as to which the Securities and Exchange
         Commission shall have granted confidential treatment.

10.12    Dispute Resolution.

         (a)      Negotiations Between Executives. The parties shall attempt in
                  good faith to resolve any dispute arising out of or relating
                  to this Agreement promptly by negotiation between executives
                  who have authority to settle the controversy and who are
                  officers of the parties' corporations. Any party may give the
                  other party written notice of any dispute not resolved in the
                  normal course of business. Within fifteen (15) days after
                  delivery of the notice, the receiving party shall submit to
                  the other a written response. The notice and the response
                  shall include (i) a statement of each party's position and a
                  summary of arguments supporting that position, and (ii) the
                  name and title of the executive who will represent that party
                  and any other person who will accompany the executive. Within
                  thirty (30) days after delivery of the disputing party's
                  notice, the executives of both parties shall meet at a
                  mutually acceptable time and place, and thereafter as often as
                  they reasonably deem necessary to attempt to resolve the
                  dispute. All reasonable requests for information made by one
                  party to the other will be honored.

                  All negotiations pursuant to this clause are confidential and
                  shall be treated as compromise and settlement negotiations for
                  purposes of applicable rules of evidence

         (b)      Mediation. If the dispute has not been resolved by negotiation
                  within forty-five (45) days of the disputing party's notice,
                  or if the parties failed to meet within thirty (30) days, the
                  parties shall attempt to settle the dispute by mediation under
                  the then current CPR Mediation Procedure. Unless otherwise
                  agreed, the parties will select a mediator from the CPR Panels
                  of Distinguished Neutrals.

         (c)      Arbitration. Any dispute arising out of or relating to this
                  Agreement or the breach, termination or validity thereof which
                  has not been resolved by the non-binding procedure specified
                  in Section 10.12(b) above within ninety (90) days of the
                  initiation of such procedure, shall be submitted to binding
                  arbitration to be administered by the American Arbitration
                  Association ("AAA") under its Commercial Arbitration Rules,
                  and judgment on the award rendered by the arbitrators may be
                  entered in any court having jurisdiction thereof. The parties
                  agree that the AAA Optional Rules for Emergency Measures of
                  Protection shall apply to the proceedings. The arbitration
                  shall be conducted in Washington, D.C. before a panel of three
                  (3) arbitrators, and the arbitrators shall have power to
                  fashion any and all remedies that would be within the
                  authority and discretion of a Federal District Court hearing
                  the same dispute.

                                      -23-
<PAGE>

                  It is the intention of the parties that discovery, although
                  permitted as described herein, will be limited except in
                  exceptional circumstances. The arbitrator shall permit such
                  limited discovery necessary for an understanding of any
                  legitimate issue raised in the procedure, including the
                  production of documents. Each party shall be permitted, but
                  not required, to take the deposition of not more than five (5)
                  persons, each such deposition nor to exceed ten (10) hours in
                  length. If the arbitrator believes that exceptional
                  circumstances exist, and additional discovery is necessary for
                  a full and fair resolution of the issue, he or she may order
                  such additional discovery as he or she deems necessary. At the
                  hearing the parties may present testimony (either by live
                  witness or deposition) and documentary evidence. The
                  arbitrator shall have sole discretion with regard to the
                  admissibility of any evidence and all other matters relating
                  to the conduct of the hearing.

                  The statute of limitations of the State of Illinois applicable
                  to the commencement of a lawsuit shall apply to the
                  commencement of an arbitration hereunder, except that no
                  defenses shall be available based upon the passage of time
                  during any negotiation or mediation called for by the
                  preceding paragraphs of this Section 10.12.

10.13    Continuing Performance. During the term of any negotiation and/or
         mediation pursuant to Section 8.5 above, and/or arbitration according
         to Section 10.12 above, ORGANICS shall continue to supply and ENDEAVOR
         shall continue to purchase Substance hereunder pending resolution of,
         and subject to the outcome of, such dispute and such obligations may be
         enforced by means of an appropriate equitable remedy in an arbitration
         proceeding as herein specified. Such continuing performance obligation
         of ORGANICS shall be contingent upon ENDEAVOR's tender of full payment
         for each order of Substance according to the terms and conditions of
         this Agreement. ORGANICS' obligation of continuing performance pursuant
         to this Section 10.13 shall cease in the event ORGANICS terminates the
         Agreement pursuant to Sections 8.2(b) or 8.2(c), or ENDEAVOR breaches
         its obligations under Sections 2.4(c) or 9.8.

10.14    No Third Party Beneficiaries. Nothing in this Agreement is intended to
         benefit and shall not be deemed to benefit any person or entity that is
         not a party hereto, or create any third party beneficiary rights.

10.15    Successors Bound. All covenants, promises, representations and
         agreements herein contained shall be binding upon, apply and inure to
         the benefit of ORGANICS and ENDEAVOR and their respective heirs, legal
         representatives, successors and assigns. Any necessary grammatical
         changes required to make the provisions of this Agreement apply either
         to corporations or individuals, men or women, singular or plural, shall
         in all cases be assumed as though in each case fully expressed.

                                      -24-
<PAGE>

WITNESS the signatures on behalf of the parties hereto by their duly authorized
representatives as of the 24th day of October, 2000.

ORGANICS/LAGRANGE, INC.              ENDEAVOR PHARMACEUTICALS, INC.

By /s/ Lois K. Hicks                 By   /s/ R. Forrest Waldon
   -----------------------------       -----------------------------------------
   Lois K. Hicks                       R. Forrest Waldon
   President                           President and Chief Executive Officer

                                      -25-
<PAGE>

                                    EXHIBIT A

                                        *

* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

<PAGE>

                                    EXHIBIT B

                                        *

* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.
<PAGE>

                                    EXHIBIT C

                                        *

* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.

<PAGE>

                                    EXHIBIT D

                                        *

* Certain information on this page has been omitted and filed separately with
the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.<PAGE>

                                                                   EXHIBIT 10.8

                          ADVERTISING AGENCY AGREEMENT

THIS AGREEMENT is made effective October 1, 2001 between Endeavor
Pharmaceuticals, Inc., a Delaware corporation, with Headquarters located at 127
Racine Drive, Suite 202, Wilmington, NC 28403 and with the Sales and Marketing
Office located at 8 Campus Drive, Third Floor East, Parsippany, NJ 07054
(hereinafter referred to as "Company") and Accel Healthcare Communications,
LLC., a Delaware limited liability company with a place of business at 30 Irving
Place, New York, NY 10003 (hereinafter referred to as "Agency").

         WHEREAS, Company is interested in retaining the services of an
advertising agency for advertising and promotional activities for CE10
(conjugated estrogens) with brand name to be determined (hereinafter referred to
as the "Product"); and

         WHEREAS, Company and Agency have executed a CONFIDENTIAL DISCLOSURE
AGREEMENT dated July 23, 2001 (the "CONFIDENTIAL DISCLOSURE AGREEMENT"); and

         WHEREAS, Agency has represented to Company that it possesses all
requisite skills, knowledge, experience and technical capabilities to perform
these services for Company;

         NOW, THEREFORE, and in consideration of the mutual promises and
covenants hereinafter set forth, Company and Agency agree as follows:

1.       AGENCY SERVICES

         Company appoints Agency to serve as Company's advertising agency on a
         non-exclusive basis in the United States with respect to such Product
         and such services as Company may designate in accordance with a
         mutually agreed upon Scope of Work. Agency agrees that it will not
         accept other clients or work on other products where such work would
         create a conflict of interest with Company's Product without the prior
         written approval of Company. The Scope of Work for 2001-2002 is
         attached to this Agreement as Schedule A and made part hereof. Company
         may from time-to-time revise the Scope of Work for reallocation of
         hours from anticipated projects to others and, such revised Scope of
         Work shall govern thereafter. In addition to the tasks outlined in the
         Scope of Work, Agency's duties shall include upon Company's request but
         not be limited to:

         1.1      Assigning and obtaining Company approval of a highly
                  professional integrated team to provide services as requested
                  in the Scope of Work. The team must represent all Agency
                  services and departments, and one person, whose identity must
                  be approved by Company, must be

                                       1
<PAGE>

                  designated as sole head of that team: Charlene Prounis,
                  Managing Partner. Agency shall also designate key leaders to
                  be the main contact for certain Agency functions. The
                  composition of the team will comply with the specifications of
                  the staffing plan, attached to this Agreement as Schedule B.

         1.2      Ensuring the team assigned to Company understands the assigned
                  Product, services and offerings, the category/industry within
                  which Company operates, and the key customer categories where
                  the assigned Product will be marketed.

         1.3      Providing monthly and quarterly reporting to Company on all
                  work performed in hours spent on Company business in a
                  mutually agreed upon format. Monthly reports will include:
                  monthly hours by project and by employee, with year-to-date
                  totals and variances from estimated hours.

         1.4      Analyzing present and potential marketing and advertising
                  opportunities and providing Company with verbal and/or written
                  (as requested) point-of-view on such.

         1.5      Analyzing and reviewing market research to provide Company
                  with timely counsel and a verbal and/or written (as requested)
                  point-of-view on implications and recommended actions.

         1.6      Providing Company with input for pre-launch and launch
                  marketing plans, which put forward reasonable proposals for
                  reaching Company objectives.

         1.7      Preparing all recommendations, materials and other elements as
                  may be necessary to present ideas to Company or as may be used
                  in the execution of ideas into finished communications.

         1.8      Supervising production of communications materials when
                  requested.

         1.9      Advising Company of the availability of all media that can be
                  appropriately used in promoting the Company Product and
                  services.

         1.10     Rendering all services necessary for the proper and efficient
                  use of all media in accordance with industry standards.

         1.11     Negotiating and arranging for the contracting for all talent
                  including residuals. All such contracts with talent shall
                  reflect the independent contractor status of the talent and
                  shall provide that Company will not be responsible for taxes
                  or benefits of any kind on behalf of the talent.

                                       2
<PAGE>

         1.12     Except as set forth herein or otherwise agreed by the parties,
                  negotiating, arranging and contracting for all photography,
                  models, special effects, etc., as required within the Scope of
                  Work for the production of communications materials whether
                  broadcast or other.

         1.13     Conducting research on and analyzing competitive spending and
                  messages when requested by the Company.

         1.14     Providing reviews and assessing implications of significant
                  industry trends, such as direct response advertising and
                  evolving FDA regulations when requested by the Company.

         1.15     Attending strategy and other meetings and performing research
                  as requested by Company.

         1.16     Providing comprehensive project management and reporting for
                  all Agency departments, which can be used to plan and track
                  all programs and projects.

         1.17     Providing other services as requested by Company and agreed to
                  by Agency with appropriate adjustments in the Scope of Work
                  and personnel assigned to the Product, if necessary.

         1.18     Coordinating and cooperating as necessary with other agencies
                  or vendors retained by Company for the Product.

2.       GENERAL TERMS

         2.1      The parties recognize that this is a non-exclusive agreement
                  and during the term hereof, Agency may act as an advertising
                  agency for other pharmaceutical or chemical manufacturers
                  provided that Agency's services for/with such other companies
                  will not create, in the judgment of Company, a conflict of
                  interest (including, but not limited to, products related to
                  menopause including vasomotor symptoms, vaginal-vulvar
                  atrophy, osteoporosis, female sexual dysfunction, androgen
                  insufficiency, rapid wasting syndrome). Agency agrees that it,
                  including subsidiary companies, will not provide the services
                  contemplated herein for any product or service, which is
                  competitive with the Product, without specific written
                  approval from Company. Additionally, no individual performing
                  services under this Agreement shall perform similar services
                  for any product or service, which is competitive with the
                  Product for any affiliate of Agency, without specific written
                  approval from Company. It is also understood that Company may
                  engage advertising agencies for the Product other than Agency.

                                       3
<PAGE>

         2.2      Agency agrees to devote its reasonable best efforts to
                  Company's interests and to attempt in every way to make
                  Company's programs successful; Company agrees to aid Agency in
                  so doing by making available to Agency needed information and
                  materials pertaining to Company's Product and to cooperate
                  with Agency in expediting its work on Company's behalf.

         2.3      Agency shall in no event place any advertisements of Company
                  in any advertising medium without first submitting the text
                  and designs therefor to Company and obtaining Company's
                  written approval. Agency agrees to comply with reasonable
                  requests of Company to deliver proposed pieces with sufficient
                  time for internal review.

                  Before incurring liability on Company's behalf for any item of
                  space or time in an advertising medium, or for artwork,
                  mechanical arts, printed matter, services or expenditures
                  within the scope of this Agreement, Agency shall obtain the
                  Company's prior written approval.

                  Agency shall be entitled to rely and act upon authorization
                  given by the members of the Company marketing team assigned to
                  work on the Product who are designated by Company in writing
                  as being empowered to give such instruction, approval, or
                  authorization as attached hereto and incorporated herein
                  Schedule C, as amended.

         2.4      Agency shall use its reasonable best efforts to guard against
                  any loss to Company through failure of media or suppliers to
                  properly execute their commitments; but Agency shall not be
                  held responsible for any failure on the part of said media or
                  suppliers, unless such failure is due to or caused by the
                  negligence of Agency. However, when media or suppliers fail to
                  properly execute their commitments, Agency shall not settle
                  any disputes regarding such deficient performance without the
                  Company's prior written approval of the form and substance of
                  such settlement. Company shall be a third party beneficiary to
                  such agreement and shall have the right to seek recourse
                  against said media or supplier and Agency hereby agrees to
                  subrogate its rights thereto, except where agreements existing
                  on the effective date of this Agreement prohibit the
                  subrogation of Agency's rights, at Company's request.

         2.5      Agency represents and warrants that performance of the
                  services required under this Agreement does not violate any
                  agreements or relationships existing between Agency and any
                  persons by whom Agency may otherwise be employed or with whom
                  Agency may have contractual arrangements.

                                       4
<PAGE>

         2.6      Agency represents and warrants that all material supplied to
                  Company or used on behalf of Company pursuant to this
                  Agreement shall either (i) not infringe the copyright of any
                  third party, or (ii) be licensed at net cost to Company under
                  a third party copyright. Company shall have the right, in its
                  discretion, to examine copies of releases obtained by Agency.
                  Agency further represents and warrants that Company shall be
                  free to use such material under this Agreement without
                  interference by or claims of third parties, subject to any
                  limitations on usage contained in the aforesaid releases,
                  licenses or other documentation and brought to the attention
                  of Company in writing prior to Company incurring any costs
                  related thereto.

                  In addition, in the event that the work carried out by Agency
                  in connection with this Agreement may utilize the names or
                  likenesses of independent third parties, Company shall not, in
                  such instance, be obligated for any additional consideration
                  or payment to such individuals, except where Agency has
                  obtained Company's prior approval to incur such additional
                  consideration or payment obligation, and Agency hereby
                  covenants and warrants that use of such names or likenesses
                  shall be legally and properly arranged.

         2.7      All documents or other materials supplied to Agency by Company
                  and/or prepared by Agency for Company under this Agreement
                  ("Work Product") shall be property of Company and shall be
                  delivered to Company at any time upon Company's request, or no
                  later than the termination of this Agreement, provided Agency
                  has been timely paid for the Work Product to be delivered.
                  Agency hereby transfers and assigns to Company any copyright
                  in such Work Product, including all of the exclusive rights
                  comprised in such copyright, whether published or unpublished
                  except for any proprietary products and software the Agency
                  developed, such as STAGES and e-visor, in which case the
                  Agency shall grant the Company a fully-paid non-exclusive
                  world-wide license in such products and software if they are
                  incorporated into any of the Company's Work Product to the
                  extent required to use such Work Product. Agency shall ensure
                  and hereby covenants that all individuals working on such Work
                  Product have assigned to Agency their rights to such Work
                  Product. Agency agrees to execute any documents necessary to
                  assign to Company Agency's full copyright interest in the Work
                  Product either solely or jointly with others for Company
                  pursuant to this Agreement. Also, it is clearly understood
                  that no restrictions will be placed on Agency by third parties
                  with respect to any Work Product without the prior written
                  consent of Company.

         2.8      Agency shall not disclose the terms of this Agreement. This
                  Agreement does not entitle Agency to use the Company's name or
                  trademarks of Company, in any way, without prior written
                  authorization.

                                       5
<PAGE>

         2.9      The parties agree that the CONFIDENTIAL DISCLOSURE AGREEMENT
                  between the parties executed on July 23, 2001 (set forth in
                  Schedule F) is hereby incorporated by reference into this
                  Agreement, except that the term of said CONFIDENTIAL
                  DISCLOSURE AGREEMENT shall continue for seven years past the
                  termination of this Agreement. Agency agrees that all
                  information (oral, written or computerized), report,
                  instrument, document or paper generated or developed for
                  Company or provided to Agency by or on behalf of Company,
                  including the terms of this Agreement, shall be considered a
                  trade secret, proprietary and confidential information of the
                  Company as defined in the CONFIDENTIAL DISCLOSURE AGREEMENT
                  (the "Confidential Information").

                  Agency agrees (i) to use the Confidential Information only in
                  connection with its performance of this Agreement; (ii) to
                  disclose the Confidential Information only to those employees
                  who need to know such Confidential Information because they
                  are assisting in the performance of the services hereunder;
                  and (iii) will not disclose Confidential Information to any
                  third-party without the prior written consent of Company, and
                  prior to such approved disclosure shall require such third
                  parties to execute a confidentiality agreement protecting
                  Confidential Information in a form approved by Company.

         2.10     Agency understands and agrees that, for purposes of this
                  Agreement, Agency and any employee(s) or other individual(s)
                  designated by Agency to perform services under this Agreement
                  ("staff members") are acting in the capacity of independent
                  contractors. Agency is responsible for staffing the project
                  and providing any and all compensation and/or benefits to its
                  staff members. Company is not responsible for withholding, and
                  shall not withhold, taxes of any kind from any payments it
                  owes to Agency unless required by law. Agency agrees to comply
                  with all laws related to withholding and payment of payroll
                  taxes related to individuals providing services hereunder.
                  Neither Agency nor any of its staff members has authority to
                  represent or act on behalf of Company without Company's prior
                  written consent. Further, as independent contractors, neither
                  Agency nor any of its staff members is eligible to participate
                  in, nor are they eligible for coverage under, any of Company's
                  benefit plans, programs, employment policies or procedures or
                  workers' compensation insurance. In consideration of Company
                  agreeing to use Agency's services hereunder, Company will be
                  released from any liability arising from Company's failure to
                  provide such plans, programs, policies, procedures and
                  workers' compensation insurance. Agency shall defend and
                  indemnify Company for any and all claims, losses, injuries or
                  damages that may be asserted against Company as an alleged
                  employer

                                       6
<PAGE>

                  with respect to any Agency employee or third party vendor
                  employee providing services in connection with this Agreement.

         2.11     Any contract or other agreement that Agency enters into with
                  any third party for purpose of implementing this Agreement
                  (hereinafter "Agency Contract") will be solely between Agency
                  and such other third party. Agency has no authority to bind
                  Company. Each such Agency Contract (i) shall contain terms,
                  conditions and covenants that are substantially similar to
                  this Agreement, including, but not limited to, obligations of
                  confidentiality, assignment of copyrights and inventions (as
                  set forth in Sections 2.7, 2.9 and 2.12, respectively), and
                  (ii) shall expressly provide that such Agency Contract neither
                  creates a third party beneficiary relationship between Company
                  and such third party, nor vests any right of action to such
                  third party against Company. Agency remains responsible for
                  the performance of third parties under Agency Contracts.
                  Agency shall defend and indemnify Company for any and all
                  claims, injuries or damages of any kind that occur in
                  connection with any Agency Contract and/or the performance
                  thereunder, and Company will not be liable in any manner in
                  connection with claims of any nature. In the event that this
                  Agreement is terminated and Company wishes to retain another
                  agency to perform the services defined in Section 1 above,
                  Agency shall, at the request of Company, assign to Company or
                  its designee any such Agency Contract(s). Accordingly, each
                  Agency Contract shall contain a clause permitting Agency to
                  assign the contract to Company.

         2.12     All information, inventions, discoveries, patent rights,
                  trademarks and copyrights which result from any services
                  performed by Agency pursuant to this Agreement ("Inventions"),
                  will be the exclusive property of Company. Agency shall
                  promptly disclose in writing to Company each such Invention
                  and provide to Company all information known to Agency
                  reasonably relating to such Invention. Agency agrees to sign
                  all necessary documents or take such other actions as Company
                  may reasonably request in order to perfect and enforce any and
                  all of its rights in such Inventions. In particular, Agency
                  shall assign to Company all of Agency's right, title and
                  interest in and to each such Invention. All costs and expenses
                  for perfecting and enforcing its rights in such Inventions
                  shall be born by Company.

3.       AGENCY COMPENSATION

         3.1      Company shall pay Agency professional fees at a blended rate
                  of $130 per hour for work performed by Agency at the request
                  of Company, consistent with the Scope of Work, as revised.
                  This fee shall be paid in monthly payments of $85,861.00, (the
                  "Pro Rata Monthly Fee") with a

                                       7
<PAGE>

                  quarterly adjustment based upon the quarterly reconciliation
                  described below. In addition, Company shall reimburse Agency
                  for direct out-of-pocket expenses incurred by Agency
                  consistent with Sections 4 and 5 hereof.

         3.2      Before commencing work on any given project, Agency will
                  provide a creative work plan/project description prior to the
                  initiation of new projects for Company approval. Agency shall
                  also submit to Company a cost estimate, including estimated
                  hours necessary for completion, and out-of-pocket expenses,
                  and shall obtain the prior written approval of Company to
                  proceed in accordance with Schedule C. Agency shall not exceed
                  the estimate by 10% for any project without prior written
                  approval by Company.

         3.3      At the beginning of each calendar month, Agency shall submit
                  an invoice to Company for the Pro Rata Monthly Fee. Payment
                  for all invoices is due within thirty (30) days of receipt of
                  original invoice by Company, unless agreed otherwise by both
                  parties. Company will not pay for any services invoiced, or
                  identified in a quarterly reconciliation, more than three (3)
                  months after such services were performed unless prior written
                  notification is provided to Company. The Agency shall
                  reconcile the hours billed by Agency for each calendar quarter
                  to the Pro Rata Monthly Fee and report on the status of the
                  project(s). Agency will provide such quarterly reconciliation,
                  outlining the total hours worked compared to projected hours
                  with the invoices for the last month in each calendar quarter.
                  The variance will be addressed through a credit in dollars to
                  the Company or as an addition in dollars to the Agency. Such
                  credit or addition shall be applied against or added to the
                  next invoice for the Pro Rata Monthly Fee.

         3.4      The total amount to be paid by Company for services rendered
                  during the term of this Agreement and for expenses incurred
                  consistent with Sections 4 and 5 shall not exceed
                  $2,482,660.00 without the prior written consent of Company.

         3.5      Any purchase order issued by Company in connection with this
                  Agreement shall be for payment purposes only, and shall not be
                  deemed a contract document and its terms and conditions shall
                  not apply.

4.       AGENCY REIMBURSEMENT

         4.1      Agency shall provide estimates of direct out of pocket
                  expenses to Company for each project. Unless indicated
                  otherwise in this Section 4, Agency shall invoice Company for
                  direct out of pocket expenses as

                                       8
<PAGE>

                  follows: (i) 20% of the project expenses as an advance upon
                  approval and start of a project, (ii) an additional 40% of the
                  project expenses as an advance at disk release or the midway
                  point of the project, as agreed to by Company, and (iii) a
                  final invoice upon the completion of the project presenting
                  total actual project expenses, that are no greater than 10% of
                  the original estimate, less any advance payments made by the
                  Company

         4.2      Company shall reimburse Agency for reasonable direct expenses
                  incurred under this Section and Section 5 within thirty (30)
                  days of its receipt of an invoice, including adequate
                  supporting documentation. Itemized expenses will be provided
                  with the final invoice for a project. Such invoice will
                  include only those expenses incurred pursuant to this Section
                  and Section 5 of the Agreement, and shall be a separate
                  invoice from that provided under Section 3. Invoices shall
                  include receipts for all items in the amount of $25.00 or
                  more, and such receipts shall be cross-referenced to the
                  invoice or project.

         4.3      Agency shall take advantage of all payment discounts offered
                  by vendors for the Company's projects. If the advance payments
                  described in Section 4.1 above does not provide the Agency
                  with adequate working capital to take advantage of interim
                  payment discounts offered by vendors or make other advance
                  payments required by vendors, Agency shall request an
                  additional advance payment from Company in order to take
                  advantage of such payment discounts or make other advance
                  payments required by vendors. Company shall be entitled to a
                  credit for any potential payment discounts not taken by
                  Agency, unless Company had instructed Agency in writing not to
                  take advantage of such payment discounts, to the extent such
                  potential discounts individually are equal to or greater than
                  $1,000.

         4.4      Agency shall submit all media and other invoices in adequate
                  time for Company to review such invoices and obtain volume and
                  cash discounts associated with the final invoice for a
                  project. Agency will indicate discount payment terms on
                  invoices to Company. Agency will follow a billing format that
                  is satisfactory to Company. Invoices must be provided to
                  Company no more than 120 days after the date the applicable
                  payment is earned unless prior written approval for delayed
                  billing is authorized by Company. Notwithstanding the
                  foregoing, Agency must provide to Company no later than the
                  first week in December an itemized list of any and all
                  expenses incurred or to be incurred hereunder prior to year
                  end, but not yet billed to Company, in order to obtain
                  reimbursement for such expenses in the following calendar
                  year.

         4.5      Agency shall not share directly or indirectly in the profits
                  of any third party in connection with Agency services
                  hereunder without the prior written consent of Company. Agency
                  shall not "mark up" or take a commission

                                       9
<PAGE>

                  for any product or service provided for Company, whether it be
                  from a third party or a corporate affiliate. Company shall be
                  entitled to a pro-rata share of any rebates received by Agency
                  from any third parties.

                                       10
<PAGE>

         4.6      Media

                  If Agency is directed to buy media space or time, costs will
                  be billed to Company at net cost (without mark-up and less all
                  discounts or rebates earned) as follows:

                  a.       Radio, newspaper, television and outdoor and on-line
                           time or space costs will be billed on an estimated
                           basis before the month in which the advertising is to
                           appear. Such invoices will be accompanied by
                           corresponding media schedules.

                  b.       Consumer and trade magazine space will be billed
                           during the month prior to the month in which the
                           advertising is to appear. Such invoices will be
                           accompanied by corresponding media schedules.

                  c.       Agency will adjust the estimated media costs to
                           actual cost and refund any overpayment to Company or
                           bill for additional charges within sixty (60) days of
                           receipt of invoices from publishers and stations.

                  d.       Agency or its designee will inspect and check tear
                           sheets for all print insertions on behalf of Company
                           and maintain a record that each ad has been verified.
                           Publications (newspapers, magazine, trade papers,
                           etc.) containing Company's advertising will be
                           retained in Agency's files for one year after
                           publication, for Company's inspection.

                  e.       Affidavits from audio and television stations will
                           also be retained in Agency's files for one year after
                           the date of the program for Company's inspection.

         4.7      Production

                  a.       Agency will commence work upon receipt of an approved
                           estimate for production costs for marketing
                           communications.

                  b.       Television, audio-visual and videotape production
                           costs will be invoiced to Company as follows: (i)
                           One-third (1/3) of total estimated cost when estimate
                           and contract have been agreed upon by Company, (ii)
                           an additional one-third (1/3) of total estimated cost
                           when filming and or taping is completed, and (iii)
                           the remaining balance of total actual cost when a
                           work print or edited tape of commercial is approved
                           by Company.

                                       11
<PAGE>

                  c.       Upon receipt of supplier invoices, Agency will submit
                           final adjustment billing as necessary, but in no case
                           later than sixty (60) days after a work print or
                           edited tape of commercial is approved by Company.

         4.8      Materials and Services

                  Postage incurred in shipping, mechanical art, copy and layout
                  will be charged at cost to Company. Postage costs incurred by
                  Agency for direct mail will be paid to Agency prior to each
                  mail date. Company shall not be liable for any portion of
                  overhead costs and/or subscriptions incurred by Agency in the
                  normal course of business, such as, but not limited to,
                  charges associated with basic telephone service and equipment
                  leases.

         4.9      Agency shall exert its reasonable best efforts to obtain for
                  Company the most favorable rates and terms for all items
                  charged to Company, shall obtain multiple bids from third
                  parties for such items, and shall comply with all existing
                  Company guidelines for soliciting bids from third parties for
                  such items. Agency will also consult with Company to determine
                  if there are approved vendors for certain categories of
                  services, and if such approved vendors exist, will utilize
                  Company approved vendors.

5.       REIMBURSEMENT OF TRAVEL AND ENTERTAINMENT COSTS

         Agency shall submit copies of all hotel bills and other reimbursable
         expenses along with the associated charges and receipts. Invoices for
         all reimbursable expenses shall list the dates, company, persons
         visited and business purpose for the expense. Receipts for expenses are
         required for all single expenditures of $25.00 or more. If Agency
         personnel conduct work on behalf of another client during travel
         related to a specific Company project, the number of hours billed to
         Company for such travel shall be reduced by the number of hours spent
         performing work on such other client's behalf. In the event travel
         and/or lodging is related to both a specific Company project and the
         business of another client, the cost of such travel, lodging and
         related expenses shall be pro-rated.

         5.1      Travel. Agency will bear the cost, without charge to Company,
                  of all normal travel expenses (out-of-pocket) of Agency
                  personnel engaged in regular activities, including travel
                  between Agency's offices and Company offices in New Jersey.
                  With the exception of the foregoing, Company will reimburse
                  Agency for the actual cost of travel expenses incurred by
                  Agency personnel when traveling at Company's request or
                  working on tight deadlines necessitating late nights (after 8
                  pm) which require Agency

                                       12
<PAGE>

                  to provide safe transportation within the Agency's policy
                  (Taxi service within NYC or to nearest suburban train
                  station).

         5.2      Airline Travel. Air travel, when requested by Company, will be
                  reimbursed by the Company. All air travel must be directly
                  related to a specific Company project. Agency shall utilize
                  the lowest available coach class airfare. The ticket stub or
                  e-ticket receipt and boarding pass must be presented with the
                  billing invoice.

         5.3      Taxi, bus, rail or car rental. Taxi, bus, rail and car rental
                  expenses along with associated receipts for tolls and parking
                  will be reimbursed by the Company. Reimbursement for car
                  rentals will be made upon presentation of a car rental
                  agreement/receipt. Car rentals must be contracted at the
                  lowest available rate and in the compact/subcompact category
                  where possible, unless special requirements dictate otherwise,
                  in which case prior Company approval is required.

         5.4      Lodging. Agency should use reasonable discretion in regards to
                  hotel selection and hotel rates. Agency shall only invoice
                  hotel expenses that are directly related to the work performed
                  under this Agreement.

         5.5      Meals and Entertainment. Working meals with Company employees
                  during normal business hours will be reimbursed by Company.
                  Billing should include names of all attendees and the subject
                  matter discussed. Meals with Company employees during
                  non-business hours will not be reimbursed. All other
                  entertainment expenses such as theater tickets etc. are
                  non-reimbursable, unless authorized in writing by a Vice
                  President of Company.

         5.6      Travel Time. The Company will be charged for travel time at
                  the lower of actual time spent traveling or five hours per day
                  when airline or long-distance (Amtrak) train is used or two
                  hours per day when car or local transportation is used, unless
                  prior written approval by Company is obtained by Agency.

         5.7      All reimbursement for travel costs will be governed by
                  Schedule E Company Corporate TRAVEL GUIDELINES.

6.       CHANGES OR SUSPENSION OF WORK

         6.1      Company may, during progress of any work hereunder, by written
                  or oral order to Agency, require additions, modifications,
                  suspension or termination of such assigned work. However, any
                  such oral orders shall

                                       13
<PAGE>

                  be confirmed in writing as soon as reasonably possible by
                  Agency or Company.

         6.2      Company reserves the right, in its sole discretion, to modify,
                  reject, cancel or stop any and all projects, plans, schedules
                  or work in progress. Company will make every effort to provide
                  Agency with reasonable notice for substantial increases or
                  reductions in assigned work. In such event, Agency shall
                  immediately take all necessary action to execute Company's
                  instructions. Provided Agency proceeds in full accordance with
                  Company's instructions, Company will assume liability and make
                  payment for all non-cancelable commitments and will pay Agency
                  for charges incurred for canceled or changed work up to the
                  date of notice of cancellation or change. The provisions of
                  this Section shall not be construed as committing either party
                  to breach any lawful contractual commitments to media.

7.       ADDITIONAL CHARGES FOR UNSCHEDULED SERVICES

         There will be no compensation under this Agreement for (i) preparation
         of any estimates or (ii) work done in connection therewith, in the
         event Agency prepares a bid or proposal for Company regardless of
         whether Agency's bid or proposal is accepted by Company.

8.       TEMPORARY/FREE-LANCE HELP

         8.1      If administrative personnel are hired through a temporary
                  employment service, they are employees of the employment
                  service. As such, their costs should be a direct out of pocket
                  expense charged to the Company without markup.

         8.2      Professional Free-lancers and independent contractors who are
                  hired by the Agency will track and report their hours in
                  accordance with this Section 3 of this agreement and have
                  their hours included and accounted for in the quarterly fee
                  reconciliation. Such independent contractors will not be
                  charged as an additional out-of-pocket expense.

9.       TERM AND TERMINATION

         9.1      This Agreement is effective as of October 1, 2001, and shall
                  continue through December 31, 2002 unless terminated by
                  Company, with or without cause, upon the giving of sixty (60)
                  days written notice to Agency.

                                       14
<PAGE>

         9.2      Upon receipt of the termination notice (the "Notice Date"),
                  Agency, at the request of and as specified by Company, shall
                  cancel all cancelable contracts and commitments entered into
                  by Agency on behalf of Company during the term of this
                  Agreement. As of the termination date, Agency shall assign to
                  Company or its designated agents non-cancelable contracts and
                  work in progress previously approved by Company. With respect
                  to such contracts and work in progress, Company shall make all
                  payments to which Agency is entitled under this Agreement
                  through the termination date.

         9.3      After the Notice Date, Company will pay Agency the lesser of
                  (i) two Pro Rata Monthly Fee payments or (ii) the difference
                  between the amount specified in Section 3.4 and the total of
                  all invoices charged or chargeable to the Company through the
                  Notice Date. Agency shall perform only those services and
                  incur only those expenses and charges that are specifically
                  requested by Company or required under this Agreement, after
                  the Notice Date. All reconciliation's required under this
                  Agreement will apply to periods through the Notice Date and no
                  such reconciliation's will be required for periods after the
                  Notice Date.

         9.4      In the event there is any credit due to Company hereunder,
                  Agency shall promptly reimburse Company for such credit within
                  thirty (30) days of the termination date.

         9.5      Following the termination of this Agreement, to the extent
                  that either Agency or Company has ownership rights, Agency
                  shall transfer to Company in the format prescribed by Company,
                  and Company shall be entitled to use, without further
                  obligation, all plans, ideas, sketches, copy, layouts,
                  commercial material, films, and the like submitted to Company
                  by Agency. Agency shall also promptly return all Company
                  property and documents in its possession.

         9.6      The obligations of the parties contained in Sections 2.4, 2.6,
                  2.7, 2.8, 2.9, 2.10, 2.11, 2.12, 9.4, 9.5, 10.1, 12, 16.4, and
                  16.5 hereof shall survive any expiration or termination of
                  this Agreement.

10.      INDEMNIFICATION AND INSURANCE

         10.1     Agency agrees to indemnify Company for, and to hold Company
                  harmless from, any damage claims, including attorneys' fees
                  and costs of suit, asserted against Company resulting from (i)
                  any breach by Agency of the representations and warranties
                  contained in Sections 2.5 and 2.6 and/or (ii) the negligent or
                  willful actions of Agency, which affect the rights or property
                  of any third party, including, but not limited to, claims
                  involving

                                       15
<PAGE>

                  copyright infringement, false or misleading statements,
                  violations of personal rights of privacy, misappropriation of
                  ideas or rights, and literary piracy or plagiarism. Agency,
                  prior to the settlement of any such claims at its own expense,
                  agrees to obtain Company's prior written approval of such
                  settlement, which shall not be unreasonably withheld.

         10.2     Company agrees to similarly indemnify and hold Agency harmless
                  with respect to, any advertising or promotion materials and
                  commercial data or material relating to the Company or
                  Product, including claims about the Product, furnished to
                  Agency by the Company specifically for inclusion or to be
                  incorporated into any advertisements or marketing or
                  promotional materials produced by Agency, as a result of which
                  claims or suits involving deceptive advertising, unfair
                  competition or product disparagement are made against Agency.
                  Company further agrees to indemnify and hold Agency harmless
                  with respect to claims related to the use or consumption of
                  Company's products in market testing or general public usage.

         10.3     Notwithstanding any other provisions of this Agreement, Agency
                  shall procure and obtain during any term of this Agreement
                  insurance in a form and with a carrier satisfactory to Company
                  as follows:

                  (a)      Worker's Compensation including Occupational Disease
                           and Employer's Liability Insurance covering all of
                           Agency's employees engaged in the performance of this
                           Agreement.

                  (b)      Commercial General Liability including personal
                           injury and broad form contractual coverages. The
                           Limit of Liability should be not less than
                           $10,000,000 combined single limits. The Certificate
                           of Insurance shall provide that Company is an
                           additional insured, and shall also provide that
                           Company is to be notified of a cancellation or
                           material change in the coverage afforded not less
                           than thirty (30) days prior to such cancellation or
                           change.

                  (c)      Advertising Agency Professional Liability Insurance
                           in an amount of not less than $10,000,000. The
                           Certificate of Insurance shall provide that Company
                           is an additional insured, and shall also provide that
                           Company is to be notified of a cancellation or
                           material change in the coverage afforded not less
                           than thirty (30) days prior to such cancellation or
                           change.

                  (d)      Certificates of the above insurance must be filed
                           with Company by Agency within ten (10) days after
                           execution of this Agreement.

                                       16
<PAGE>

                           Certificates shall provide at least thirty (30) days
                           prior notice of cancellation or non-renewal of
                           coverage.

11.      AUTHORIZED PERSONNEL

         Agency may rely on authorized employees per Schedule C or agents
         designated in writing by Company to approve with signature or initials
         any media placement, advertising copy, graphic, product, marketing
         programs and any activity necessary for completion of any project
         assigned to Agency.

12.      AUDIT AND ACCOUNTING

         12.1     Company's Right to Review Agency's Books

                  During the term of this Agreement and one year thereafter,
                  Company or an audit firm engaged by Company shall have the
                  right upon ten (10) business days notice, to review Agency's
                  books, records, systems, processes and accounting practices as
                  they pertain to services rendered to Company. Agency shall
                  maintain complete records including individual time-keeping
                  cards, the cost of all materials and services purchased and
                  work subcontracted to other parties, requests for proposal and
                  bids. Such records shall be maintained under good internal
                  control practices, in accordance with GAAP and in such a
                  manner as may be readily audited. Such records, including all
                  supporting documents, shall be available at Agency's premises.

         12.2     Changes in the Agency's Cost Accounting

                  Agency will not change its cost accounting system, policies or
                  practices during the term of this Agreement unless ninety (90)
                  days written notice is provided to Company. Such notice should
                  describe in adequate detail the nature of changes proposed and
                  the impact, if any, to Company. The Company will not be
                  invoiced or charged in any way for added costs resulting from
                  any change in Agency's cost accounting system without
                  Company's prior written approval.

13.      ASSIGNMENT

         This Agreement may be assigned by Company as part of the sale of
         substantially all of its business, or may be assigned by Company to a
         company controlled by it, or controlling it, or under common control
         with it. Agency agrees

                                       17
<PAGE>

         that if this Agreement is assigned to any such company, all the terms
         and conditions of this Agreement shall remain between such other
         company and itself with the same force and effect as if said Agreement
         had been with such other company in the first instance. This Agreement
         is deemed personal to Agency, and Agency shall therefore have no right
         or authority to assign this Agreement or any portion thereof or
         otherwise delegate its performance under this Agreement.

                                       18
<PAGE>

14.      NOTICES

         Any formal notices permitted or required hereunder shall be in writing
         and shall be deemed to have been given on the date of delivery if
         delivered, or on the date of receipt, if mailed by registered mail,
         postage prepaid, at the respective addresses below or at such other
         address as either party hereto may designate by notice pursuant hereto.

         All notices forwarded to Company shall be sent as follows:

                  Ms. Kathleen Milligan,
                  Vice President, Marketing
                  Endeavor Pharmaceuticals, Inc.
                  8 Campus Drive, 3rd Floor
                  Parsippany, NJ 07054
                  Telephone (973) 683-0070
                  Facsimile (973) 683-0075

          With a copy to:

                  Mr. Stephen F. Rizzo
                  Vice President and Chief Financial Officer.
                  Endeavor Pharmaceuticals, Inc.
                  Racine Drive, Suite 202
                  Wilmington, NC 28403
                  Telephone (910) 790-9811
                  Facsimile (910) 790-9041

         All notices forwarded to Agency shall be sent to:

                  Ms. Charlene Prounis
                  Managing Partner
                  Accel Healthcare Communications
                  30 Irving Place
                  New York, NY 10003
                  Telephone (646) 602-6904
                  Facsimile (646) 602-6901

15.      COMPANY BUSINESS PRACTICES

         Agency recognizes that it is Company's policy to comply with all
         applicable laws, regulations, permits and consent orders and to act in
         a proper and ethical manner. Accordingly, in connection with the
         services provided hereunder for

                                       19
<PAGE>

         Company, Agency agrees to comply with all applicable laws, regulations,
         permits and consent orders. The Company may terminate this Agreement
         immediately, without penalty or payment contemplated by Section 9.3, in
         the event that Agency breaches the terms of this Section.

16.      MISCELLANEOUS PROVISIONS

         16.1     The waiver of any breach of this Agreement by either party
                  shall not constitute a waiver as to any future breach. This
                  Agreement embodies the entire agreement of the parties hereto
                  with respect to the subject matter hereof and supersedes any
                  and all previous agreements, oral or written, between Agency
                  and Company. This Agreement and any Schedules attached hereto
                  may not be modified or changed except in writing signed by
                  both parties. In the event of any inconsistency between the
                  Agreement and any attachment hereto, the terms of the
                  Agreement shall prevail.

         16.2     Neither party shall be liable for the failure to perform its
                  obligations under this Agreement if such failure is occasioned
                  by a contingency beyond such party's reasonable control,
                  including, but not limited to, strikes or other labor
                  disturbances, lockouts, riots, wars, terrorist attacks, fires,
                  earthquakes, floods or storms. A party claiming a right to
                  excused performance under this Section shall immediately
                  notify the other party in writing of the extent of its
                  inability to perform, which notice shall specify the
                  occurrence beyond its reasonable control that prevents such
                  performance.

         16.3     In the event of the merger of Agency into or with any other
                  entity, or the acquisition of Agency or its assets by any
                  entity, or the insolvency or bankruptcy, or the reorganization
                  or recapitalization which results in a change in the
                  controlling parties of Agency, or its making a general
                  assignment for the benefit of creditors, this Agreement may be
                  terminated forthwith in whole or in part in the sole and
                  absolute discretion of Company without liability or payment
                  contemplated by Section 9.3 attaching to Company as a result
                  thereof.

         16.4     This Agreement shall be governed by the laws of the State of
                  North Carolina as if made in and to be performed in North
                  Carolina, without regard to its choice of law principles.

         16.5     Agency agrees that Company and any of Company's affiliated
                  companies or assignees may use any of the materials produced
                  under this Agreement by Agency.

                                       20
<PAGE>

         16.6     The Section headings of this Agreement are merely for the
                  convenience of the parties and are not to be construed as
                  modifying or changing the obligations or conditions expressed
                  in this Agreement.

         16.7     Debarment.

                  (a)      Agency hereby certifies that it has not been debarred
                           under the provisions of the Generic Drug Enforcement
                           Act of 1992, 21 U.S.C. Sec. 335a(a) and (b). In the
                           event that during the term of this Agreement Agency
                           (i) becomes debarred; or (ii) receives notice of an
                           action or threat of an action with respect to its
                           debarment, Agency agrees to immediately notify
                           Company. Agency also agrees that in the event that it
                           becomes debarred it shall immediately cease all
                           activities relating to this Agreement.

                  (b)      In the event that Agency becomes debarred, this
                           Agreement shall automatically terminate, without any
                           further action or notice by either party. In the
                           event that Company receives notice from Agency or
                           otherwise becomes aware that (i) a debarment action
                           has been brought against Agency; or (ii) Agency has
                           been threatened with a debarment action, then Company
                           shall have the right to terminate this Agreement
                           immediately without further liability, including any
                           payment contemplated by Section 9.3, to Company.

                  (c)      Agency hereby certifies that it has not and will not
                           use in any capacity the services of any individual,
                           corporation, partnership or association which has
                           been debarred under 21 U.S.C. Sec. 335a(a) or (b). In
                           the event that Agency becomes aware of the debarment
                           or threatened debarment of any individual,
                           corporation, partnership or association providing
                           services to Agency which directly or indirectly
                           relate to the activities under this Agreement, Agency
                           shall notify Company immediately. Upon the receipt of
                           such notice by Company or if Company otherwise
                           becomes aware of such debarment or threatened
                           debarment, Company shall have the right to terminate
                           this Agreement immediately without further liability,
                           including any payment contemplated by Section 9.3, to
                           Company.

                     (This space intentionally left blank.)

                                       21
<PAGE>

         IN WITNESS WHEREOF, the parties by their duly authorized
representatives have caused this Agreement to be executed as of the respective
date written above.

Accel Healthcare Communications, LLC.       Endeavor Pharmaceuticals, Inc.

By:                                         By:
   ---------------------------------           ---------------------------------

Name:                                       R. Forrest Waldon
     -------------------------------

Title:                                      President and Chief Executive
      ------------------------------        Officer

                                       22
<PAGE>

                                   SCHEDULE A

                              AGENCY SCOPE OF WORK

EXHIBIT 1 provides 2002 detail and Agreement totals

EXHIBIT 2 provides 2001 detail

                                       23

<PAGE>
                          ADVERTISING AGENCY AGREEMENT
                            SCHEDULE A -- EXHIBIT 1
                             Scope of Work -- 2002

<TABLE>
<CAPTION>
                                                                       FEE                               PRINTING AND
PROJECT                                                   HOURS    (HRS X $130)    OOPS     ADDITIONAL    PRODUCTION    OTHER COSTS
<S>                                                       <C>      <C>            <C>       <C>          <C>            <C>
Strategic Planning/General (50 hours/month)                600       $ 78,000     $ 12,000                 $    --       $     --
DDMAC Material Preparation                                 200         26,000       20,000
Enjuvia Logo Development                                   200         26,000       20,000
Enjuvia Message Development                                200         26,000        5,000
Media Planning and Maintenance                             250         32,500        3,000
General and Administration (25 hours/month)                300         39,000        6,000
Travel and Expenses                                                                 25,000

CONCEPT DEVELOPMENT

Positioning/Creative Development                           400         52,000       50,000      25,000
Market Research Concept Testing                            300         39,000       20,000
Package Insert                                              50          6,500        5,000

JOURNAL AD

Launch Ad + Brief Summary                                  225         29,250       25,000

CORPORATE PROMOTION                                                        --

Creative Development                                       150         19,500       45,000      29,750
Corporate Panel                                            150         19,500       22,000      10,000       1,500
Corporate Brochure (100,000)                               175         22,750       25,000      10,000      45,000

DIRECT SELLING MATERIAL                                                    --

Sales Aid (2500)                                           450         58,500       45,000
File Card (30,000)                                         200         26,000       20,000
Annotated Sales Aid (1000)                                 200         26,000       10,000
Patient Brochure (500,000)                                 200         26,000       45,000      15,000
Patient Brochure on Menopause (1,000,000)                  200         26,000       30,000      10,000
Dosing Card (30,000)                                       150         19,500        7,500
Reprint Carriers x 2 (60,000)                              300         39,000       15,000
Waiting Room Display (30,000)                              200         26,000       15,000
PharmAlert (solo mailing)                                  100         13,000       10,000       5,000
Telephone Message Pads (100,000)                            50          6,500        5,000
Wholesaler Stocking Package                                150         19,500       20,000       7,500
Pharmacy Sell Sheet (100,000)                              100         13,000       10,000
Product Monograph (30,000)                                 400         52,000       45,000      15,000
Sample Closet Shelf Talker                                 225         29,250       20,000
Claims Support Document                                    100         13,000        5,000
Sample Packet Design                                       200         26,000       15,000      10,000
Trade Label                                                100         13,000        5,000

Formulary Kit (10,000)                                     300         39,000       40,000      20,000      12,000
Strategy Development                                       100         13,000        5,000

DIRECT-TO-PATIENT

Concept Development                                        300         39,000       50,000      30,000
Market Research (preparation and attendance)               150         19,500       20,000       5,000
Direct Mail or Pharmacy Package                            235         30,550       20,000

DIRECT MAIL

Mediscripts                                                 75          9,750        5,000
Announcement Mailer Med/Pharm Alert (2)
(1 solo; 1 co-op)                                          150         19,500        8,000                 80,000

OPPORTUNISTIC SPENDING (PRODUCT AND PROGRAM OUTCOMES)      500         65,000      250,000

    NEW PROGRAMS (TBD)                                     707         91,910
                                                           ----------------------------------------------------------------------
TOTAL 2002 BUDGET                                         9042    $ 1,175,460  $ 1,003,500   $ 192,250   $ 138,500       $    --
TOTAL 2001 BUDGET (EXHIBIT 1)                              865        112,450       52,750
                                                                  ------------------------------------------------
GRAND TOTALS                                              9907    $ 1,287,910  $ 1,056,250   $ 192,250   $ 138,500
                                                                  ===========                =====================
PRINTING AND PRODUCTION TOTAL                                                  $   138,500
                                                                               -----------
SUM OF OOPS/PRINTING/PRODUCTION                                                $ 1,194,750
                                                                               ===========

TOTAL FEES                                                        $ 1,287,910
TOTAL OPPS/PRINTING/PRODUCTION                                      1,194,750
                                                                  -----------
SUM OF FEES AND OOPS/PRINTING/PRODUCTION                          $ 2,482,660
                                                                  ===========
</TABLE>

Note: OOP grand total for '02 is $1,056,250 which is inclusive of the additional
$192,250

                                      21-1

<PAGE>
                          ADVERTISING AGENCY AGREEMENT
                             SCHEDULE A - EXHIBIT 2
                              Scope of Work - 2001

<TABLE>
<CAPTION>
                                                                                                      PRINTING
                                                   PROJECTED     FEE       DEVELOPMENT                   AND           OTHER
PROJECT                                              HOURS   (HRS X $130)     OOPS       ADDITIONAL   PRODUCTION       COSTS
                                                                                                                     ITEM  AMOUNT
<S>                                                   <C>    <C>           <C>           <C>           <C>           <C>
Strategic Planning/General (50 hours/month)           150    $   19,500    $       --    $       --    $       --    $       --
Name Development                                       25         3,250            --
General and Administration (25 hours/month)            75         9,750           500
Travel and Expenses                                    --                      25,000
Landscape Research (preparation and attendance)       125        16,250
Brand Research (preparation and attendance)           200        26,000           500
CORPORATE PROMOTION                                                  --
Internal Message Discovery                             10         1,300            --
Competitive Messages                                   25         3,250           250
Questionnaire/Summary/Brand Workshop (2)               50         6,500         1,500
Market Research (preparation and attendance) (2)       80        10,400         5,000
Positioning/Tag lines/Message Development              50         6,500            --
Logo Development                                       75         9,750        20,000        10,000
                                                      ---------------------------------------------------------------------------
TOTAL BUDGET                                          865    $  112,450    $   52,750    $   10,000    $       --    $       --
                                                      ===========================================================================
</TABLE>

                                      21-2

<PAGE>

                                   SCHEDULE B

                              AGENCY STAFFING PLAN

ACCEL STAFFING PLAN - 2001 AND 2002

<TABLE>
<S>                                                                        <C>
                                                                              %
Partner, Advertising (Charlene Prounis)                                     25
Partner (James Pelletier, Co-Chief Creative Officer)                        25
Group Account Supervisor (Michael Banner)                                   70
Account Executive (TBD)                                                    100
Assistant Account Executive                                                 25
Creative Director, Art (Maria Casini)                                       25
Art Director (Adam Cohen)                                                  100
Copywriter (Sal Diana)                                                     100
Traffic/WP/Editorial/Support                                                70

                                                                         Hours
Total  hours = 5.4 FTE x 1,820 hours/employee                            9,907
</TABLE>

Time charges for highly skilled creative artists are not contemplated above and
will be invoiced to Company as out of pocket expenses. Agency shall provide an
estimate of such expenses and obtain Company approval prior to incurring any
such expenses.

100% of employee time is equal to 1,800 hours. This includes vacation, holidays,
summer Fridays and training days.

                                       24

<PAGE>

                                   SCHEDULE C

                          COMPANY AUTHORIZED EMPLOYEES

FORREST WALDON, PRESIDENT & CEO

         -      Responsible for the strategic direction of the Company

         -      Will sign off on expenditures greater than $300,000.

KATHLEEN MILLIGAN, VICE PRESIDENT, MARKETING & SALES

         -      Responsible for overseeing the strategic direction of the
                Company and its brands.

         -      Will sign off on Scope of Work.

         -      Will sign off on selected creative work plans/project
                descriptions, media plans, marketing materials and estimates.

         -      Will sign off on expenditures up to $300.000.

LUCY HUTCHISON, SENIOR DIRECTOR, MARKETING

         -      Responsible for strategic direction of the Company and its
                brands.

         -      Responsible for overseeing day-to-day strategy and tactical
                execution of programs developed with Agency.

         -      Will sign off on Scope of Work.

         -      Will sign off on creative work plans/project descriptions, media
                plans, marketing materials and estimates.

         -      Will sign off on expenditures up to $100,000.

DAVID TEMPLETON, PRODUCT DIRECTOR

         -      Responsible for the day-to-day strategy and tactical execution
                of programs developed with Agency.

         -      Will act as primary "day-to-day" contact.

         -      Will sign off on creative work plans/project descriptions, media
                plans, marketing materials and estimates.

         -      Responsible for internal budget tracking of agency fees and
                OOPs.

         -      Will sign off on expenditures up to $10,000.

Any amendments to the Agreement, other than changes and adjustments to project
scope that do not result in an overall increase in Company liability, will
require the prior

                                       25

<PAGE>

approval of either R. Forrest Waldon or Stephen F. Rizzo, Vice President and
Chief Financial Officer.

                                       26

<PAGE>

                                   SCHEDULE D

                                    NOT USED

                                       27

<PAGE>

                                   SCHEDULE E

                       COMPANY CORPORATE TRAVEL GUIDELINES

Agency is responsible to ensure that each Agency Employee complies fully with
this guideline. Although this guideline does mention Agency Employees, the
purpose of this guideline is to determine how Company will reimburse Agency for
its expenses.

I.       Responsibility and Enforcement

Company will not reimburse Agency Employees or even review individual expense
reports, but rather only Agency invoices containing information on expenses
incurred. Company may see supporting documentation if requested for any expenses
it is being requested to reimburse.

The appropriate Company contact or their designees are responsible for reviewing
invoices for accuracy, ensuring compliance with travel expenses and guidelines
outlined in this agreement, and providing guidance regarding reasonable business
expenditures.

The Company will reimburse Agency for all reasonable and necessary expenses, as
more fully delineated in this agreement, while traveling or performing
authorized Company business.

The Company will not reimburse expenses that are not in compliance with this
agreement and travel guidelines, unless an exception authorization is obtained
in advance in writing. (see Section V. Policy Deviations).

Agency Employees who do not comply with travel expenses outlined in this
agreement may subject Agency invoices to delay or withholding of reimbursements.
Any falsification or misrepresentation of names, events, amounts or other
explanations, whether for personal gain or to deceive the person approving any
expense report or for any other reason , is prohibited and considered a serious
disciplinary offense which may subject the Agency to serious consequences, up to
and including termination.

II.      Travel - Guidelines

         A.       Air and Rail Travel

         Agency Employees purchasing tickets for travel on business for the
Company must purchase the most economical airline tickets or business class rail
accommodations.

                                       28

<PAGE>

         The exchange of tickets at airline counters or at other travel agencies
for cash or other personal gain is prohibited.

         B.       Lowest Airfare Definition

         Individuals should be booked using the lowest coach class airfares
available and consistent with business needs. These fares are determined based
on the following parameters.

                  -        specially negotiated fares;

                  -        nonrefundable fares when changes are not expected;
                           and

                  -        Saturday night stay over

         Full fare tickets may be issued for trips, which require frequent
changes, however, approval by Company is required.

         An Agency Employee cannot decline an airline or hotel accommodation
because of preferred frequent flyer programs or other incentives for the Agency
Employee's benefit.

         C.       Domestic Travel

         Domestic travel is defined as travel to any of the 50 United States,
Canada, Puerto Rico, or the Virgin Islands.

         All domestic air travel must be in coach class, except when medically
restricted. Agency Employees should make every effort to book the most direct,
economical carrier consistent with business needs.

         D.       International Travel

         International travel covers all travel other than that previously
described as domestic.

         Any International travel must have prior written authorization from the
Company Vice President of Sales & Marketing.

         E.       Flight Insurance

         Individual flight insurance is not reimbursable.

                                       29

<PAGE>

         F.       Denied Boarding Compensation

         Airlines occasionally offer free tickets or cash allowances to
compensate individuals for delays or inconveniences due to overbooking, flight
cancellations, or changes of equipment. Agency Employees must not volunteer for
denied boarding compensation when on Company business and on Company time.

         G.       Lost Baggage

         The airlines have the ultimate responsibility for retrieving and
compensating for lost baggage. Company will not reimburse Agency Employees for
personal items lost while traveling on business. Company encourages the
following steps to be taken to minimize losses:

         -        carry valuables on board the aircraft;

         -        carry important or confidential documents on board the
                  aircraft; and

         -        tag luggage with name, business address, and phone number

         Losses not covered by the airlines should be pursued with Agency
insurance coverage or the Agency Employee's homeowner's or renter's insurance.
Company has no responsibility or liability for loss items

         H.       Bonus Award Programs

         Agency Employees who participate in bonus award or frequent flyer
programs may retain for personal credit any bonus awards they receive from
business travel, as long as the Agency Employee's accommodations or reservations
are made in accordance with this policy. Fees required for participation are not
reimbursable as a business expense. Travelers cannot refuse an accommodation,
airline carrier, or other authorized vendor because of the loss of bonus credits
or program points.

III.     Reimbursement of Travel/Business Expenses

         In the course of business, certain expenses are incurred by the Agency
Employees which can be categorized as reimbursable. The determination of
reimbursable expenses relies partially on the tax deductibility of those
expenses, as specified in the IRS regulations. Company also realizes that the
nature and amount of travel and business related expenditures may vary with the
objectives of each assignment and surrounding circumstances. Managers are
responsible for clearly

                                       30

<PAGE>

communicating the travel and reimbursement policy to all Agency Employees and
how it is applied. The Agency is expected to be in full compliance with these
policies and will be held accountable for unauthorized policy deviations.

         All travel and business expenses must be approved by Company before the
expense is incurred.

         All expenses must be reported, supported and approved prior to
reimbursement, and receipts covering such expenses must be included with Agency
invoices.

         A.       Reimbursable expenses

                  The following business expenses are reimbursable:

                  1.       Travel expenses

                           a.       Air and Rail Travel

                                    All arrangements must be made at the lowest
                                    fare available. Ticket stubs or passenger
                                    receipts (in the case of electronic
                                    ticketing) and the itinerary are to be
                                    attached to the Agency Invoice.

                           b.       Limousine Service

                                    A receipt must be included from the driver,
                                    and this receipt, along with the itinerary
                                    must be attached to the Agency Invoice.

                           c.       Taxi and Airport Limo/Shuttle Service

                                    The cost of taxis, limos or shuttles to or
                                    from places of business, hotels, airports,
                                    or railroad stations is reimbursable. Agency
                                    Employees should use scheduled bus or
                                    shuttle services to and from airports or
                                    hotels, wherever possible.

                           d.       Vehicle Rental

                                    Vehicle rental expenses are reimbursable
                                    when the vehicle is rented for business use.
                                    Agency Employees should rent a compact car
                                    unless:

                                       31

<PAGE>

                                    -        there are two or more Agency
                                             Employees traveling together;

                                    -        they are escorting customers in the
                                             vehicle; and/or

                                    -        they need a large trunk to carry
                                             business material or exhibit items

                                    The deciding factors for renting a vehicle
                                    should be the location you are traveling to
                                    or from, and the availability of public
                                    transportation, not personal convenience or
                                    anticipated personal use.

                                    Agency Employees should adhere to Agency
                                    policies on whether or not to accept
                                    Collision Damage and Personal Accident
                                    Insurance for vehicles rented for domestic
                                    (or international) travel for business
                                    purposes. Company will not reimburse for
                                    collision damage and personal accident
                                    insurance or waivers or any other type of
                                    insurance or waivers associated with rental
                                    vehicles.

                                    Rental agreements and receipts must be
                                    retained and attached to Agency invoice.
                                    Vehicles should be fueled to capacity before
                                    returning the rental vehicle to the return
                                    station. Retain and submit all receipts for
                                    gas or oil purchases. If the vehicle is not
                                    fueled to capacity, an explanation as to why
                                    should be included.

                                    Express check out slips are not receipts,
                                    however they will be accepted if they are
                                    submitted with the original rental
                                    agreement.

                  2.       Lodging

                           Hotel expenses are reimbursable at a cost, which is
                  usual for the area being visited. A standard single room is
                  normally acceptable, however, deluxe accommodations may be
                  requested if the business need exists, (e.g., a suite if
                  interviewing or local management meetings). Any such upgrades
                  must be approved by Company in writing prior to booking.

                           A detailed hotel receipt must be attached to the
                  Agency invoice. The bill must be marked paid, show a zero
                  balance, or be accompanied

                                       32

<PAGE>

                  by a charge card receipt. All categories of charges (e.g.,
                  room rate and tax, phone, room service) must be itemized
                  separately on a daily basis.

                                       33

<PAGE>

                  3.       Meals, Entertainment, and Other Living Expenses

                           a.       Meals

                                    Personal meals are defined as meal expenses
                           incurred by the Agency Employee when dining alone as
                           a result of a Company requested business trip or
                           business function. Meals are reimbursed according to
                           actual and reasonable cost. The cost of meals should
                           include tips and taxes. Receipts must be submitted
                           for any single expense of $25 or more. Charge card
                           receipts are preferred. Restaurant stubs are not
                           accepted. Meals must be itemized separately for
                           breakfast, lunch and dinner.

                           b.       Business Meal Expenses

                                    Business meals are defined as those meals
                           during which a specific Company business discussion
                           takes place. Agency will be reimbursed for business
                           meal expenses according to actual and reasonable
                           costs. Receipts are required for all business meals.
                           The documentation for business meals must include the
                           name(s) of the person(s) being entertained, their
                           business affiliation and title, and the purpose of
                           the business meeting.

                           c.       Documentation and IRS Requirements

                                    The IRS and Company require the following
                           documentation for meals and entertainment:

                           -        an original receipt must be submitted with
                                    the expense report;

                           -        names of the individuals entertained, their
                                    titles, and company affiliation;

                           -        name and location of where the meal or event
                                    took place;

                           -        exact amount and date of the expense;

                           -        specific business topic discussed; and

                           -        in the case of entertainment events, the
                                    time the discussion took place (i.e.,
                                    before, during or after)

                                       34

<PAGE>

                           d.       Gratuities

                                    Reasonable tips are reimbursable as
                           determined by level of service and local custom. As a
                           general rule, employees should not tip more than they
                           would on a personal trip. All tips, other than those
                           for meals (e.g., skycap, bellman, or housekeeping)
                           should be reported separately on the expense report.

                                    Lavish or unreasonable gratuities as
                           determined by Company will not be reimbursed.

                           e.       Laundry and Valet Service

                                    Company will not reimburse for any laundry
                           or valet service.

                           f.       Telephone

                                    Business related phone and fax charges are
                           reimbursable. This includes calls to home while
                           traveling on Company business. Good judgment should
                           dictate the need, duration and number of calls.
                           Company expects every individual to use good
                           financial judgment when deciding how the calls should
                           be made (e.g., credit card, cell phone, hotel or long
                           distance).

                           g.       Other Reimbursable Expenses

                                    Agency will be reimbursed for the following
                                    miscellaneous expenses:

                                    -        air freight for Company business
                                             purposes;

                                    -        direct business office expenses
                                             (e.g., copies, faxes);

                                    -        overnight delivery of business
                                             materials;

                                    -        parking when at a location other
                                             than Agency site;

                                    -        seminar fees with prior company
                                             approval

                                    Agency will not be reimbursed for the
                                    following expenses:

                                       35

<PAGE>

                                    -        airline club membership dues;

                                    -        baby-sitting;

                                    -        barbers, hairdressers, and any
                                             other personal service;

                                    -        clothing;

                                    -        dry cleaning;

                                    -        charge card delinquency fees;

                                    -        commuting expenses between
                                             employees' residence and place of
                                             work, even if working overtime or
                                             scheduled day off;

                                    -        country club dues;

                                    -        excess baggage charges (unless it
                                             is business materials);

                                    -        expenses not supported by a voucher
                                             or receipt without adequate
                                             explanation;

                                    -        flight insurance;

                                    -        flowers, fruit baskets, cakes, etc.
                                             to fellow employee or their
                                             relative, when they are ill, have a
                                             birthday, have a baby, death in
                                             family, etc.;

                                    -        golf fees;

                                    -        gum, candy, cigarettes or
                                             toiletries;

                                    -        health club facility fees, saunas,
                                             massages;

                                    -        in flight telephone charges;

                                    -        loss or theft of personal property
                                             or funds;

                                    -        lost baggage;

                                       36

<PAGE>

                                    -        magazines, books, newspapers;

                                    -        mini bar refreshments and/or
                                             snacks;

                                    -        movies (including in flight and
                                             hotel in house movies);

                                    -        no show charges for hotel or car
                                             service;

                                    -        parking or traffic tickets;

                                    -        personal accident insurance;

                                    -        personal entertainment;

                                    -        pet care;

                                    -        post cards;

                                    -        rental car upgrades;

                                    -        shoeshine;

                                    -        souvenirs/personal gifts;

                                    -        travel companions' traveling costs

                                             Agency overhead costs

                           h.       Miscellaneous Expenses

                                    Any miscellaneous expense not mentioned
                                    above should be approved, prior to incurring
                                    the expense, by the Company. A clear
                                    explanation of the business purpose must be
                                    attached to the receipt or the IRS will
                                    disallow the deduction.

         4.       Expense Reporting

                  a.       Timing and submission

                           Agency Employees should include expense reimbursement
                           reports with each invoice to Company for the expense.

                                       37

<PAGE>

                  b.       Approval Process

                           Expense reports submitted to Company for
                           reimbursement will be reviewed (for reasonableness
                           and policy compliance).

                           All expense reports are subject to audit for such
                           things as:

                           -        accuracy;

                           -        approval signatures;

                           -        business purpose;

                           -        supporting documentation and receipts; and

                           -        policy compliance

                  c.       Documentation

                           All Agency or Agency Employee expenses must have the
                           following information in order to be reimbursed for
                           expenditures:

                           -        business purpose;

                           -        names of individuals present, their titles,
                                    and Company name;

                           -        name and location of where meal or event
                                    took place;

                           -        exact amount and date of each expense; and

                           -        in the case of entertainment events, when
                                    the business discussion took place

                           The following documentation must be supplied:

                           -        air/rail - original passenger coupon plus
                                    itinerary;

                           -        hotel - hotel folio plus charge card
                                    receipt;

                                       38

<PAGE>

                           -        vehicle rental - vehicle rental agreement,
                                    charge card receipt, or express check out
                                    form;

                           -        meals/entertainment - (expenses of $25 or
                                    more) charge card receipt or cash register
                                    receipt (no tear off stubs); and

                           -        other expenses - (of $25 or more) original
                                    charge card or cash register receipts.

                           Original receipts must be submitted whenever
                           possible. Photocopies will be accepted only with a
                           detailed explanation as to why the original is not
                           available.

IV.      Other

         A.       Group and Meeting Travel

                  Any assemblage of 10 or more people, Agency Employee and/or
                  Company, to a common destination for a common purpose is
                  considered a group. Every effort should be made to negotiate
                  group discounts on such trips. This includes negotiating and
                  contracting for guest rooms, meeting space, audio visual
                  equipment, food functions, ground and air transportation,
                  discounts, commissions and extra amenities, as well as
                  auditing and processing all invoices.

V.       Policy Deviations

         Except where otherwise specified above, any deviations from this policy
         must be reviewed and approved by the appropriate Company Vice President
         or Marketing Director.

                                       39

<PAGE>

                                   Schedule F
                        CONFIDENTIAL DISCLOSURE AGREEMENT

                     (Insert copy of CDA in final agreement)

                                       40

<PAGE>

                        CONFIDENTIAL DISCLOSURE AGREEMENT

This Confidential Disclosure Agreement (hereinafter "Agreement') is made this
23rd day of July, 2001 by and between Endeavor Pharmaceuticals, Inc., a Delaware
corporation, located at 127 Racine Drive, Wilmington, North Carolina
28403.(hereinafter "Endeavor"), and Accel Healthcare Communications, LLC., a
Delaware limited liability company located at 25 West 43rd Street, New York, NY
10036 (hereinafter "Accel").

                                   WITNESSETH

         WHEREAS, Endeavor proposes to disclose certain proprietary and
confidential information ("CONFIDENTIAL INFORMATION") to Accel as more fully
defined below;

         WHEREAS, said CONFIDENTIAL INFORMATION is being disclosed for the sole
and limited purpose of Accel performing certain services for and on behalf of
Endeavor;

         WHEREAS, Accel has agreed to keep said CONFIDENTIAL INFORMATION secret
and confidential during the term of this Agreement and to make no use of it
whatsoever except as expressly authorized by Endeavor in writing.

         NOW THEREFORE, in consideration of the disclosure of CONFIDENTIAL
INFORMATION to be provided pursuant to this Agreement and in consideration of
the covenants set forth hereinafter, and for other good and valuable
consideration, the receipt and sufficiency of which is hereby acknowledged, the
parties hereto do agree as follows;

         1.       CONFIDENTIAL INFORMATION shall mean information relating to,
without limitation, inventions, trade secrets, know-how, processes, methods of
use, methodologies, analytical procedures, clinical procedures, clinical
protocols, clinical results, compositions of matter, formulations, experimental
results, raw material sources, patent applications, business plans, financial
models, and/or marketing strategies whether written, electronic, graphic, oral,
or physical samples and specimens, furnished or disclosed by Endeavor directly
or indirectly to Accel with the exception only of the following:

         a)       information that is now in the public domain or subsequently
                  enters the public domain without fault on the part of Accel;

         b)       information that is presently known to Accel from its own
                  sources which Accel can demonstrate by written records; or

         c)       information Accel lawfully receives from any third party not
                  under any obligation to keep such information confidential.

         2.       Accel agrees not to use CONFIDENTIAL INFORMATION for any
purpose other than for Accel to perform certain services for and on behalf of
Endeavor.

<PAGE>

         3.       Accel agrees that it will maintain in confidence all
CONFIDENTIAL INFORMATION. In this regard, Accel agrees to disclose CONFIDENTIAL
INFORMATION only to those of its officers and employees who are directly,
concerned with the use and evaluation of the CONFIDENTIAL INFORMATION for the
purpose specified above, and it shall take all necessary and reasonable
precautions to prevent such CONFIDENTIAL INFORMATION from being disclosed to an
unauthorized person, firm, or company. Prior to disclosing CONFIDENTIAL
INFORMATION to its officers and employees, Accel shall advise said officers and
employees of the confidential nature thereof, and shall take all necessary and
reasonable precautions to prevent the unauthorized disclosure of the
CONFIDENTIAL INFORMATION by such officers and employees, including requiring
each such recipient to execute an appropriate Confidential Disclosure Agreement
protecting Endeavor's Confidential Information.

         4.       Accel further acknowledges that any violation of the
provisions hereof may result in irreparable injury to Endeavor for which there
is no adequate remedy at law, and Accel agrees that, in the event of any breach
of the provisions hereof, Endeavor shall be entitled to injunctive relief in
addition to any other remedy at law or in equity which may be available to
Endeavor. The parties hereto also agree that any court proceeding arising out of
a breach of the provisions hereof shall be brought in New Hanover County, North
Carolina, and that the General Court of Justice, New Hanover County, North
Carolina, shall have jurisdiction over any proceedings arising out of a breach
of this Agreement.

         5.       The obligations of Accel set forth in this Agreement shall
continue for a period of seven (7) years from the date of the execution of this
Agreement.

         6.       This Agreement may only be changed by another written
agreement signed by both of the parties hereto.

         7.       This Agreement shall inure to the benefit of and be binding
upon the undersigned parties, their respective legal successors and assigns.

         8.       This Agreement shall be governed and construed in accordance
with the laws of the State of North Carolina, U.S.A.

         9.       This Agreement shall be executed in duplicate originals with
each party retaining one original for its records.

<PAGE>

         IN WITNESS WHEREOF, Endeavor and Accel have each caused this instrument
to be executed in its corporate name by a duly authorized officer.

ACCEL HEALTHCARE COMMUNICATIONS, LLC

By:      /s/ Risa Bernstein
         -----------------------------------
         Risa Bernstein

Title:   President
         -----------------------------------

ENDEAVOR PHARMACEUTICALS, INC.

By:      /s/ Kathleen Milligan
         ---------------------------
         Kathleen Milligan
         Vice President

<PAGE>
INDEX

             1.     Agency Services
             2.     General Terms
             3.     Agency Compensation
             4.     Agency Reimbursement
             5.     Reimbursement Of Travel And Entertainment Costs
             6.     Changes Or Suspension Of Work
             7.     Additional Charges For Unscheduled Services
             8.     Temporary /Free-Lance Help
             9.     Term And Termination
            10      Indemnification And Insurance
            11.     Authorized Personnel
            12.     Audit And Accounting
            13.     Assignment
            14.     Notices
            15.     Company Business Practices
            16.     Miscellaneous Provisions

            Schedule A  Scope of Work
            Schedule B  Agency Staffing Plan
            Schedule C  Company Authorized Employees
            Schedule D  NOT USED
            Schedule E  General Company Corporate Travel Guidelines
            Schedule F  Confidential Disclosure Agreement

                                       41

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}]]